Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Ronald Jones

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Microbial Sensitivity Tests

Chemicals & Drugs

Physiology

Living Beings

Activities & Behaviors

Quality Control

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
181
Sader, Helio
173
Pfaller, Michael
110
Biedenbach, Douglas
81
Erwin, ME
58
Fritsche, Thomas
50
Barry, Arthur
42
Barrett, MS
40
Gales, Ana
39
Doern, Gary
35
Deshpande, Lalitagauri
34
Marshall, SA
33
Hollis, Richard
30
Johnson, DM
27
Messer, Shawn
24
Beach, Mondell

Sign-in to see all Coauthors

Publications

TOP 3
Mendes R E; Spanu T; Deshpande L; Castanheira M; Jones R N; Fadda G
Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy.
Castanheira M; Debbia E; Marchese A; Jones R N
Emergence of a plasmid mediated bla (VIM-1) in Citrobacter koseri: report from the SENTRY Antimicrobial Surveillance Program (Italy).
Jones Ronald N; Fritsche Thomas R; Sader Helio S
Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Ronald Jones (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Mendes R E; Spanu T; Deshpande L; Castanheira M; Jones R N; Fadda G
Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2009;15(6):588-92.
2009: Castanheira M; Debbia E; Marchese A; Jones R N
Emergence of a plasmid mediated bla (VIM-1) in Citrobacter koseri: report from the SENTRY Antimicrobial Surveillance Program (Italy).
Journal of chemotherapy (Florence, Italy) 2009;21(1):98-100.
2008: Jones Ronald N; Fritsche Thomas R; Sader Helio S
Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates.
Antimicrobial agents and chemotherapy 2008;52(10):3763-75.
2008: Castanheira Mariana; Wanger Audrey; Kruzel Mark; Deshpande Lalitagauri M; Jones Ronald N
Emergence and clonal dissemination of OXA-24- and OXA-58-producing Acinetobacter baumannii strains in Houston, Texas: report from the SENTRY Antimicrobial Surveillance Program.
Journal of clinical microbiology 2008;46(9):3179-80.
2008: Castanheira Mariana; Mendes Rodrigo E; Rhomberg Paul R; Jones Ronald N
Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007).
Microbial drug resistance (Larchmont, N.Y.) 2008;14(3):211-6.
2008: Rybak Michael J; Leonard Steve N; Rossi Kerri L; Cheung Chrissy M; Sader Helio S; Jones Ronald N
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
Journal of clinical microbiology 2008;46(9):2950-4.
2008: Jones Ronald N; Biedenbach Douglas J; Ambrose Paul G; Wikler Matthew A
Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.
Diagnostic microbiology and infectious disease 2008;62(1):110-2.
2008: Mera Robertino; Miller Linda A; Fritsche Thomas R; Jones Ronald N
Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine.
Microbial drug resistance (Larchmont, N.Y.) 2008;14(2):101-7.
2008: Mendes Rodrigo E; Deshpande Lalitagauri M; Castanheira Mariana; DiPersio Joseph; Saubolle Michael A; Jones Ronald N
First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.
Antimicrobial agents and chemotherapy 2008;52(6):2244-6.
2008: Biedenbach Douglas J; Jones Ronald N; Fritsche Thomas R
Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.
Diagnostic microbiology and infectious disease 2008;61(2):240-4.
2008: Jones Ronald N; Kirby Jeffrey T; Rhomberg Paul R
Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
Diagnostic microbiology and infectious disease 2008;61(2):203-13.
2008: Castanheira Mariana; Jones Ronald N; Sader Hélio S
Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).
Diagnostic microbiology and infectious disease 2008;61(2):235-9.
2008: Fritsche Thomas R; Sader Helio S; Jones Ronald N
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Diagnostic microbiology and infectious disease 2008;61(1):86-95.
2008: Lodise Thomas P; Patel Nimish; Renaud-Mutart Amy; Gorodecky Evgeny; Fritsche Thomas R; Jones Ronald N
Pharmacokinetic and pharmacodynamic profile of ceftobiprole.
Diagnostic microbiology and infectious disease 2008;61(1):96-102.
2008: Fritsche Thomas R; Castanheira Mariana; Miller George H; Jones Ronald N; Armstrong Eliana S
Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America.
Antimicrobial agents and chemotherapy 2008;52(5):1843-5.
2008: Ambrose Paul G; Anon Jack B; Bhavnani Sujata M; Okusanya Olanrewaju O; Jones Ronald N; Paglia Margaret R; Kahn James; Drusano George L
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis.
Diagnostic microbiology and infectious disease 2008;61(1):13-20.
2008: Fritsche Thomas R; Rhomberg Paul R; Sader Helio S; Jones Ronald N
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.
The Journal of antimicrobial chemotherapy 2008;61(5):1092-8.
2008: Jones Ronald N; Fritsche Thomas R; Moet Gary J
In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.
Diagnostic microbiology and infectious disease 2008;61(1):76-9.
2008: Fritsche T R; Biedenbach D J; Jones R N
Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006).
Journal of chemotherapy (Florence, Italy) 2008;20(2):170-4.
2008: Mendes Rodrigo E; Fritsche Thomas R; Sader Helio S; Jones Ronald N
Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(8):1324-6.
2008: Castanheira Mariana; Fritsche Thomas R; Sader Hélio S; Jones Ronald N
RmtD 16S RNA methylase in epidemiologically unrelated spm-1-producing Pseudomonas aeruginosa isolates from Brazil.
Antimicrobial agents and chemotherapy 2008;52(4):1587-8; author reply 1588.
2008: Tsuji Brian T; Leonard Steven N; Rhomberg Paul R; Jones Ronald N; Rybak Michael J
Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum.
Diagnostic microbiology and infectious disease 2008;60(4):441-4.
2008: Fritsche Thomas R; Rhomberg Paul R; Sader Helio S; Jones Ronald N
In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Diagnostic microbiology and infectious disease 2008;60(4):399-403.
2008: Mendes Rodrigo E; Sader Helio S; Deshpande Lalitagauri; Jones Ronald N
Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers.
Diagnostic microbiology and infectious disease 2008;60(4):433-6.
2008: Jones R N
Key considerations in the treatment of complicated staphylococcal infections.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2008;14 Suppl 2():3-9.
2008: Sader Helio S; Fritsche Thomas R; Jones Ronald N
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2008;52(3):1153-5.
2008: Fritsche Thomas R; Rhomberg Paul R; Sader Helio S; Jones Ronald N
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
Antimicrobial agents and chemotherapy 2008;52(3):1187-9.
2008: Galles A C; Jones R N; Sader H S
Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Journal of chemotherapy (Florence, Italy) 2008;20(1):38-42.
2008: Sader H S; Watters A A; Fritsche T R; Jones R N
Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers.
Journal of chemotherapy (Florence, Italy) 2008;20(1):28-32.
2008: Mendes Rodrigo E; Bell Jan M; Turnidge John D; Yang Qiwen; Yu Yunsong; Sun Ziyong; Jones Ronald N
Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid (blaKPC-2 plus qnrB4) and a blaIMP-4 gene.
Antimicrobial agents and chemotherapy 2008;52(2):798-9.
2008: Chin Judy N; Jones Ronald N; Sader Helio S; Savage Paul B; Rybak Michael J
Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
The Journal of antimicrobial chemotherapy 2008;61(2):365-70.
2008: Castanheira Mariana; Sader Hélio S; Deshpande Lalitagauri M; Fritsche Thomas R; Jones Ronald N
Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.
Antimicrobial agents and chemotherapy 2008;52(2):570-3.
2008: Garza-Ramos U; Tinoco P; Silva-Sanchez J; Morfin-Otero R; Rodriguez-Noriega E; Leon-Garnica G; Sader H S; Jones R N
Metallo-beta-lactamase IMP-18 is located in a class 1 integron (In96) in a clinical isolate of Pseudomonas aeruginosa from Mexico.
International journal of antimicrobial agents 2008;31(1):78-80.
2007: Jones Ronald N; Sader Helio S; Fritsche Thomas R; Janechek Michael J
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.
Diagnostic microbiology and infectious disease 2007;59(4):467-72.
2007: Sader Helio S; Mallick Rajiv; Kuznik Andreas; Fritsche Thomas R; Jones Ronald N
Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
International journal of antimicrobial agents 2007;30(6):514-20.
2007: Rhomberg Paul R; Deshpande Lalitagauri M; Kirby Jeffrey T; Jones Ronald N
Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
Diagnostic microbiology and infectious disease 2007;59(4):425-32.
2007: Tato M; Coque T M; Ruíz-Garbajosa P; Pintado V; Cobo J; Sader H S; Jones R N; Baquero F; Cantón R
Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45(9):1171-8.
2007: Lodise T P; Nau R; Kinzig M; Drusano G L; Jones R N; Sörgel F
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
The Journal of antimicrobial chemotherapy 2007;60(5):1038-44.
2007: Jones Ronald N; Fritsche Thomas R; Sader Helio S; Ross James E
LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Diagnostic microbiology and infectious disease 2007;59(3):309-17.
2007: Jones Ronald N; Fritsche Thomas R; Sader Helio S; Ross James E
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Diagnostic microbiology and infectious disease 2007;59(2):199-209.
2007: Rennie Robert P; Koeth Laura; Jones Ronald N; Fritsche Thomas R; Knapp Cindy C; Killian Scott B; Goldstein Beth P
Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.
Journal of clinical microbiology 2007;45(10):3151-4.
2007: Jones Ronald N; Nilius Angela M; Akinlade Bolanle K; Deshpande Lalitagauri M; Notario Gerard F
Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections.
Antimicrobial agents and chemotherapy 2007;51(9):3381-4.
2007: Biedenbach Douglas J; Bell Jan M; Sader Helio S; Fritsche Thomas R; Jones Ronald N; Turnidge John D
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
International journal of antimicrobial agents 2007;30(2):143-9.
2007: Lodise Thomas P; Nau Roland; Kinzig Martina; Jones Ronald N; Drusano G L; Sörgel Fritz
Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2007;58(4):445-52.
2007: Mendes Rodrigo E; Castanheira Mariana; Toleman Mark A; Sader Helio S; Jones Ronald N; Walsh Timothy R
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Antimicrobial agents and chemotherapy 2007;51(7):2611-4.
2007: Jones Ronald N; Kirby Jeffrey T; Messer Shawn A; Sheehan Daniel J
Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.
Diagnostic microbiology and infectious disease 2007;58(3):371-4.
2007: Curcio Daniel; Fernández Francisco; Jones Ronald N; Ferraro Mary Jane; Reller L Barth; Schreckenberger Paul C; Sader Helio S
Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view.
Journal of clinical microbiology 2007;45(6):2095; author reply 2095-6.
2007: Tam V H; Louie A; Fritsche T R; Deziel M; Liu W; Brown D L; Deshpande L; Leary R; Jones R N; Drusano G L
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
The Journal of infectious diseases 2007;195(12):1818-27.
2007: Deshpande Lalitagauri M; Fritsche Thomas R; Moet Gary J; Biedenbach Douglas J; Jones Ronald N
Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program.
Diagnostic microbiology and infectious disease 2007;58(2):163-70.
2007: Jones Ronald N; Sader Helio S; Stilwell Matthew G; Fritsche Thomas R
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2007;58(1):1-7.
2007: Jones Ronald N; Fritsche Thomas R; Sader Helio S; Stilwell Matthew G
Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Diagnostic microbiology and infectious disease 2007;58(1):9-17.
2007: Sader Helio S; Fritsche Thomas R; Jones Ronald N
In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
Diagnostic microbiology and infectious disease 2007;58(1):27-32.
2007: Fritsche Thomas R; Sader Helio S; Jones Ronald N
Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Diagnostic microbiology and infectious disease 2007;58(1):19-26.
2007: Jones Ronald N; Knapp Cindy C; Dowzicky Michael J
Influence of polysorbate-80 when determining the tigecycline MIC by the reference method.
Diagnostic microbiology and infectious disease 2007;58(1):145-6.
2007: Sader Helio S; Ferraro Mary J; Reller L Barth; Schreckenberger Paul C; Swenson Jana M; Jones Ronald N
Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae.
Journal of clinical microbiology 2007;45(5):1640-3.
2007: Bell Jan M; Chitsaz Mohsen; Turnidge John D; Barton Mary; Walters Luke J; Jones Ronald N
Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program.
Journal of clinical microbiology 2007;45(5):1478-82.
2007: Toleman Mark A; Bennett Peter M; Bennett David M C; Jones Ronald N; Walsh Timothy R
Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes.
Emerging infectious diseases 2007;13(4):559-65.
2007: Walsh T R; Toleman M A; Jones R N
Comment on: Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals.
The Journal of antimicrobial chemotherapy 2007;59(4):799-800; author reply 800-1.
2007: Pfaller Michael A; Sader Helio S; Jones Ronald N
Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).
Diagnostic microbiology and infectious disease 2007;57(4):459-65.
2007: Jones Ronald N; Stilwell Matthew G; Hogan Patricia A; Sheehan Daniel J
Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program.
Antimicrobial agents and chemotherapy 2007;51(4):1491-3.
2007: Jacobs Michael R; Jones Ronald N; Giordano Philip A
Oral beta-lactams applied to uncomplicated infections of skin and skin structures.
Diagnostic microbiology and infectious disease 2007;57(3 Suppl):55S-65S.
2007: Ross James E; Fritsche Thomas R; Sader Helio S; Jones Ronald N
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
International journal of antimicrobial agents 2007;29(3):295-301.
2007: Biedenbach Douglas J; Ross James E; Fritsche Thomas R; Sader Helio S; Jones Ronald N
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
Journal of clinical microbiology 2007;45(3):998-1004.
2007: Sader Helio S; Hsiung Andre; Fritsche Thomas R; Jones Ronald N
Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.
Diagnostic microbiology and infectious disease 2007;57(3):341-4.
2007: Pottumarthy Sudha; Sader Helio S; Jones Ronald N
Bactericidal activity of cefepime and ceftriaxone tested against Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2007;57(3):345-9.
2007: Moet Gary J; Dowzicky Michael J; Jones Ronald N
Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci.
Diagnostic microbiology and infectious disease 2007;57(3):333-6.
2007: Sader Helio S; Jones Ronald N
Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections.
Expert review of anti-infective therapy 2007;5(1):29-43.
2007: Aboufaycal H; Sader H S; Rolston K; Deshpande L M; Toleman M; Bodey G; Raad I; Jones R N
blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program.
Journal of clinical microbiology 2007;45(2):614-5.
2007: Rhomberg Paul R; Jones Ronald N
Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
Diagnostic microbiology and infectious disease 2007;57(2):207-15.
2007: Anon Jack B; Paglia Margaret; Xiang Jim; Ambrose Paul G; Jones Ronald N; Kahn James B
Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis.
Diagnostic microbiology and infectious disease 2007;57(1):105-7.
2007: Jones Ronald N; Ferraro Mary Jane; Reller L Barth; Schreckenberger Paul C; Swenson Jana M; Sader Helio S
Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.
Journal of clinical microbiology 2007;45(1):227-30.
2007: Moet Gary J; Jones Ronald N; Biedenbach Douglas J; Stilwell Matthew G; Fritsche Thomas R
Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Diagnostic microbiology and infectious disease 2007;57(1):7-13.
2007: Jones Ronald N; Sader Helio S; Fritsche Thomas R; Pottumarthy Sudha
Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Diagnostic microbiology and infectious disease 2007;57(1):109-16.
2007: Castanheira Mariana; Sader Hélio S; Jones Ronald N; Debbia Eugenio; Picão Renata C; Gales Ana C
In71, an Enterobacter cloacae blaVIM-1-carrying integron related to In70.2 from Italian Pseudomonas aeruginosa isolates: a SENTRY Antimicrobial Surveillance Program report.
Microbial drug resistance (Larchmont, N.Y.) 2007;13(2):130-4.
2007: Sader Helio S; Watters Amy A; Fritsche Thomas R; Jones Ronald N
Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
BMC infectious diseases 2007;7():29.
2006: Deshpande Lalitagauri M; Jones Ronald N; Fritsche Thomas R; Sader Helio S
Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004).
International journal of antimicrobial agents 2006;28(6):578-81.
2006: Kosowska-Shick Klaudia; Smith Kathy; Bogdanovich Tatiana; Ednie Lois M; Jones Ronald N; Appelbaum Peter C
Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.
Antimicrobial agents and chemotherapy 2006;50(12):4191-4.
2006: Deshpande Lalitagauri M; Rhomberg Paul R; Sader Helio S; Jones Ronald N
Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005).
Diagnostic microbiology and infectious disease 2006;56(4):367-72.
2006: Fedler Kelley A; Biedenbach Douglas J; Jones Ronald N
Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
Diagnostic microbiology and infectious disease 2006;56(4):427-36.
2006: Smith Patrick F; Tsuji Brian; Booker Brent M; Forrest Alan; Bajic Sanela; Kelchlin Pamela; Bhavnani Sujata M; Jones Ronald N; Ambrose Paul G
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model.
Diagnostic microbiology and infectious disease 2006;56(4):379-86.
2006: Andrade Soraya S; Sader Helio S; Jones Ronald N; Pereira Andrea S; Pignatari Antônio C C; Gales Ana C
Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?
Memórias do Instituto Oswaldo Cruz 2006;101(7):741-8.
2006: Ribeiro J; Mendes R E; Domingos R; França E; Silbert S; Jones R N; Sader H S
Microbiological and epidemiological characterization of imipenem-resistant Pseudomonas aeruginosa strains from a Brazilian tertiary hospital: report from the SENTRY Antimicrobial Surveillance Program.
Journal of chemotherapy (Florence, Italy) 2006;18(5):461-7.
2006: Deshpande Lalitagauri M; Sader Helio S; Fritsche Thomas R; Jones Ronald N
Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004).
Journal of clinical microbiology 2006;44(10):3775-7.
2006: Jevitt Laura A; Thorne Grace M; Traczewski Maria M; Jones Ronald N; McGowan John E; Tenover Fred C; Brown Steven D
Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates.
Journal of clinical microbiology 2006;44(9):3098-104.
2006: Sader Helio S; Jones Ronald N
The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(6):798-9; author reply 799-800.
2006: Sader H S; Streit J M; Fritsche T R; Jones R N
Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(9):844-52.
2006: Kirby Jeffrey T; Fritsche Thomas R; Jones Ronald N
Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America).
Diagnostic microbiology and infectious disease 2006;56(1):75-82.
2006: Pfaller Michael A; Sader Helio S; Fritsche Thomas R; Jones Ronald N
Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Diagnostic microbiology and infectious disease 2006;56(1):63-8.
2006: Rhomberg Paul R; Fritsche Thomas R; Sader Helio S; Jones Ronald N
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Diagnostic microbiology and infectious disease 2006;56(1):57-62.
2006: Johnson David M; Stilwell Matthew G; Fritsche Thomas R; Jones Ronald N
Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).
Diagnostic microbiology and infectious disease 2006;56(1):69-74.
2006: Fritsche Thomas R; Rennie Robert P; Goldstein Beth P; Jones Ronald N
Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.
Journal of clinical microbiology 2006;44(8):2988-90.
2006: Mariani Paul G; Sader Helio S; Jones Ronald N
Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
The Journal of antimicrobial chemotherapy 2006;58(2):481-3.
2006: Jones Ronald N; Sader Helio S
Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?
Diagnostic microbiology and infectious disease 2006;55(4):351-6.
2006: Jones Ronald N; Sader Helio S; Fritsche Thomas R; Hogan Patricia A; Sheehan Daniel J
Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
Journal of clinical microbiology 2006;44(7):2622-5.
2006: Jones Ronald N; Fritsche Thomas R; Sader Helio S; Ross James E
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.
Antimicrobial agents and chemotherapy 2006;50(7):2583-6.
2006: Sader Helio S; Fritsche Thomas R; Jones Ronald N
Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
Antimicrobial agents and chemotherapy 2006;50(7):2330-6.
2006: Huynh Holly K; Biedenbach Douglas J; Jones Ronald N
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
Diagnostic microbiology and infectious disease 2006;55(3):241-3.
2006: Pfaller Michael A; Jones Ronald N;
Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003).
Archives of pathology & laboratory medicine 2006;130(6):767-78.
2006: Johnson David M; Fritsche Thomas R; Sader Helio S; Jones Ronald N
Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions.
International journal of antimicrobial agents 2006;27(6):557-60.
2006: Biedenbach Douglas J; Toleman Mark A; Walsh Timothy R; Jones Ronald N
Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Diagnostic microbiology and infectious disease 2006;55(2):119-27.
2006: Fedler Kelley A; Jones Ronald N; Sader Helio S; Fritsche Thomas R
Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
Diagnostic microbiology and infectious disease 2006;55(2):157-64.
2006: Messer Shawn A; Jones Ronald N; Fritsche Thomas R
International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).
Journal of clinical microbiology 2006;44(5):1782-7.
2006: Streit Jennifer M; Jones Ronald N; Toleman Mark A; Stratchounski Leonid S; Fritsche Thomas R
Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003).
International journal of antimicrobial agents 2006;27(5):367-75.
2006: Watters Amy A; Jones Ronald N; Leeds Jennifer A; Denys Gerald; Sader Helio S; Fritsche Thomas R
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
The Journal of antimicrobial chemotherapy 2006;57(5):914-23.
2006: Gales A C; Jones R N; Sader H S
Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(4):315-21.
2006: Rhomberg Paul R; Fritsche Thomas R; Sader Helio S; Jones Ronald N
Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004).
Diagnostic microbiology and infectious disease 2006;54(4):249-57.
2006: Sader Helio S; Fritsche Thomas R; Jones Ronald N
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents.
Journal of clinical microbiology 2006;44(3):1101-4.
2006: Deshpande Lalitagauri M; Sader Helio S; Debbia Eugenio; Nicoletti Giuseppe; Fadda Giovanni; Jones Ronald N;
Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Diagnostic microbiology and infectious disease 2006;54(3):157-64.
2006: Bhavnani Sujata M; Ambrose Paul G; Craig William A; Dudley Michael N; Jones Ronald N;
Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2006;54(3):231-6.
2006: Goldstein Beth P; Jones Ronald N; Fritsche Thomas R; Biedenbach Douglas J
Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
Diagnostic microbiology and infectious disease 2006;54(2):83-7.
2006: Fernandez-Cuenca F; Martinez-Martinez L; Amblar G; Biedenbach D J; Jones R N; Pascual A
Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2006;12(2):197-8.
2006: Jones Ronald N; Stilwell Matthew G; Sader Helio S; Fritsche Thomas R; Goldstein Beth P
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Diagnostic microbiology and infectious disease 2006;54(2):149-53.
2006: Pottumarthy Sudha; Fritsche Thomas R; Jones Ronald N
Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes.
Diagnostic microbiology and infectious disease 2006;54(2):127-34.
2006: Jones Ronald N; Ross James E; Fritsche Thomas R; Sader Helio S
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
The Journal of antimicrobial chemotherapy 2006;57(2):279-87.
2006: Hammel Jeffrey P; Bhavnani Sujata M; Jones Ronald N; Forrest Alan; Ambrose Paul G
Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables.
Antimicrobial agents and chemotherapy 2006;50(1):62-7.
2006: Jones Ronald N; Li Qing; Kohut Bruce; Biedenbach Douglas J; Bell Jan; Turnidge John D
Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia.
Diagnostic microbiology and infectious disease 2006;54(1):63-71.
2006: Jones Ronald N
Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42 Suppl 1():S13-24.
2006: Jones Ronald N; Sader Helio S; Fritsche Thomas R; Rhomberg Paul R
Carbapenem susceptibility discords among Acinetobacter isolates.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;42(1):158.
2006: Biedenbach Douglas J; Toleman Mark; Walsh Timothy R; Jones Ronald N
Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Diagnostic microbiology and infectious disease 2006;54(1):13-21.
2006: Deshpande Lalitagauri M; Jones Ronald N; Fritsche Thomas R; Sader Helio S
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004).
Microbial drug resistance (Larchmont, N.Y.) 2006;12(4):223-30.
2006: Castanheira Mariana; Gales Ana C; Pignatari Antonio C C; Jones Ronald N; Sader Hélio S
Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Microbial drug resistance (Larchmont, N.Y.) 2006;12(2):91-8.
2005: Sader H S; Rhomberg P R; Jones R N
In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii.
Journal of chemotherapy (Florence, Italy) 2005;17(6):622-7.
2005: Jones R N; Fritsche T R; Sader H S; Goldstein B P
Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
Journal of chemotherapy (Florence, Italy) 2005;17(6):593-600.
2005: Jones Ronald N; Mendes Caio; Turner Philip J; Masterton Robert
An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
Diagnostic microbiology and infectious disease 2005;53(4):247-56.
2005: Ross James E; Jones Ronald N
Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods.
Journal of clinical microbiology 2005;43(12):6212-3.
2005: McDermott Patrick F; Bodeis-Jones Sonya M; Fritsche Thomas R; Jones Ronald N; Walker Robert D
Broth microdilution susceptibility testing of Campylobacter jejuni and the determination of quality control ranges for fourteen antimicrobial agents.
Journal of clinical microbiology 2005;43(12):6136-8.
2005: Fritsche T R; Stilwell M G; Jones R N
Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11(12):974-84.
2005: Jones Ronald N; Critchley Ian A; Whittington William L H; Janjic Nebojsa; Pottumarthy Sudha
Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains.
Diagnostic microbiology and infectious disease 2005;53(4):311-7.
2005: Sader Helio S; Fritsche Thomas R; Jones Ronald N
Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003).
Diagnostic microbiology and infectious disease 2005;53(4):329-32.
2005: Jones Ronald N; Fritsche Thomas R; Ge Yigong; Kaniga Koné; Sader Helio S
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
The Journal of antimicrobial chemotherapy 2005;56(6):1047-52.
2005: Streit Jennifer M; Sader Helio S; Fritsche Thomas R; Jones Ronald N
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
Diagnostic microbiology and infectious disease 2005;53(4):307-10.
2005: Fritsche Thomas R; Jones Ronald N
Importance of understanding pharmacokinetic/pharmacodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureus.
Journal of drugs in dermatology : JDD 2005;4(6 Suppl):s4-8.
2005: Pottumarthy Sudha; Sader Helio S; Fritsche Thomas R; Jones Ronald N
Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
Diagnostic microbiology and infectious disease 2005;53(3):225-31.
2005: Wu L-T; Hung S-W; Chuang Y-C; Chen H-E; Jones R N; Yu W-L
Identification of a novel cephalosporinase (DHA-3) in Klebsiella pneumoniae isolated in Taiwan.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11(11):893-7.
2005: Gales Ana C; Jones Ronald N; Andrade Soraya S; Pereira Andrea S; Sader Hélio S
In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2005;9(5):348-56.
2005: Gales Ana C; Jones Ronald N; Andrade Soraya S; Sader Helio S
Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002).
Memórias do Instituto Oswaldo Cruz 2005;100(6):571-7.
2005: Pottumarthy Sudha; Yu Yunson; Sader Helio S; Jones Ronald N; Chen Minjun
Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta-lactams.
Diagnostic microbiology and infectious disease 2005;53(2):131-41.
2005: Hirakata Yoichi; Matsuda Junichi; Miyazaki Yoshitsugu; Kamihira Shimeru; Kawakami Sayoko; Miyazawa Yukihisa; Ono Yasuo; Nakazaki Nobuhiko; Hirata Yasuyoshi; Inoue Matsuhisa; Turnidge John D; Bell Jan M; Jones Ronald N; Kohno Shigeru;
Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).
Diagnostic microbiology and infectious disease 2005;52(4):323-9.
2005: Sader Helio S; Fritsche Thomas R; Kaniga Koné; Ge Yigong; Jones Ronald N
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
Antimicrobial agents and chemotherapy 2005;49(8):3501-12.
2005: Fritsche Thomas R; Sader Helio S; Toleman Mark A; Walsh Timothy R; Jones Ronald N
Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41 Suppl 4():S276-8.
2005: Sader Helio S; Fritsche Thomas R; Jones Ronald N
Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Diagnostic microbiology and infectious disease 2005;52(3):265-73.
2005: Jones Ronald N; Craig William A; Ambrose Paul G; Dudley Michael N; Pottumarthy Sudha
Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
Diagnostic microbiology and infectious disease 2005;52(3):235-46.
2005: Fritsche Thomas R; Strabala Patty A; Sader Helio S; Dowzicky Michael J; Jones Ronald N
Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
Diagnostic microbiology and infectious disease 2005;52(3):209-13.
2005: Sader Helio S; Jones Ronald N; Dowzicky Michael J; Fritsche Thomas R
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Diagnostic microbiology and infectious disease 2005;52(3):203-8.
2005: Fritsche Thomas R; Sader Helio S; Stilwell Matthew G; Dowzicky Michael J; Jones Ronald N
Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Diagnostic microbiology and infectious disease 2005;52(3):195-201.
2005: Fritsche Thomas R; Sader Helio S; Stilwell Matthew G; Dowzicky Michael J; Jones Ronald N
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Diagnostic microbiology and infectious disease 2005;52(3):187-93.
2005: Sader Helio S; Jones Ronald N; Stilwell Matthew G; Dowzicky Michael J; Fritsche Thomas R
Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
Diagnostic microbiology and infectious disease 2005;52(3):181-6.
2005: Anderegg Tamara R; Sader Helio S; Fritsche Thomas R; Ross James E; Jones Ronald N
Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
International journal of antimicrobial agents 2005;26(1):13-21.
2005: Jones Ronald N; Fritsche Thomas R; Sader Helio S
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2005;52(2):129-33.
2005: Pottumarthy Sudha; Deshpande Lalitagauri M; Sader Helio S; Jones Ronald N
Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
Diagnostic microbiology and infectious disease 2005;52(2):95-9.
2005: Stelling John M; Travers Karin; Jones Ronald N; Turner Philip J; O'Brien Thomas F; Levy Stuart B
Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs.
Emerging infectious diseases 2005;11(6):873-82.
2005: Jones Ronald N; Sader Helio S; Fritsche Thomas R
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
Diagnostic microbiology and infectious disease 2005;52(1):71-4.
2005: Rhomberg Paul R; Jones Ronald N
Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels.
Diagnostic microbiology and infectious disease 2005;52(1):67-9.
2005: Ross James E; Anderegg Tamara R; Sader Helio S; Fritsche Thomas R; Jones Ronald N
Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Diagnostic microbiology and infectious disease 2005;52(1):53-8.
2005: Booker Brent M; Smith Patrick F; Forrest Alan; Bullock Julie; Kelchlin Pamela; Bhavnani Sujata M; Jones Ronald N; Ambrose Paul G
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.
Antimicrobial agents and chemotherapy 2005;49(5):1775-81.
2005: Sader Helio S; Jones Ronald N
Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp.
International journal of antimicrobial agents 2005;25(5):380-4.
2005: Fritsche Thomas R; Sader Helio S; Cleeland Roy; Jones Ronald N
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Antimicrobial agents and chemotherapy 2005;49(4):1468-76.
2005: Pottumarthy Sudha; Fritsche Thomas R; Sader Helio S; Stilwell Matthew G; Jones Ronald N
Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
International journal of antimicrobial agents 2005;25(4):282-9.
2005: Streit Jennifer M; Steenbergen Judith N; Thorne Grace M; Alder Jeffrey; Jones Ronald N
Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis.
The Journal of antimicrobial chemotherapy 2005;55(4):574-8.
2005: Ross James E; Sader Helio S; Fritsche Thomas R; Jones Ronald N
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels.
Diagnostic microbiology and infectious disease 2005;51(3):219-21.
2005: Rhomberg Paul R; Sader Helio S; Jones Ronald N
Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content.
International journal of antimicrobial agents 2005;25(3):274-6.
2005: Pottumarthy Sudha; Fritsche Thomas R; Jones Ronald N
Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997-2003).
Diagnostic microbiology and infectious disease 2005;51(2):147-50.
2005: Jones Ronald N; Sader Helio S; Fritsche Thomas R
Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis).
Diagnostic microbiology and infectious disease 2005;51(2):139-41.
2005: Jones Ronald N; Biedenbach Douglas J; Sader Helio S; Fritsche Thomas R; Toleman Mark A; Walsh Timothy R
Emerging epidemic of metallo-beta-lactamase-mediated resistances.
Diagnostic microbiology and infectious disease 2005;51(2):77-84.
2005: Jones Ronald N; Anderegg Tamara R; Swenson Jana M;
Quality control guidelines for testing gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods.
Journal of clinical microbiology 2005;43(2):925-7.
2005: Gales A C; Sader H S; Jones R N
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11(2):95-100.
2005: Sader Helio S; Jones Ronald N
Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli.
International journal of antimicrobial agents 2005;25(2):95-109.
2005: Bell Jan M; Turnidge John D; Inoue Matsuhisa; Kohno Shigeru; Hirakata Yoichi; Ono Yasuo; Jones Ronald N
Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan.
The Journal of antimicrobial chemotherapy 2005;55(2):276-8.
2005: Pottumarthy Sudha; Fritsche Thomas R; Jones Ronald N
Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: validation report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2005;51(1):57-62.
2005: Bhavnani Sujata M; Hammel Jeffrey P; Jones Ronald N; Ambrose Paul G
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.
Diagnostic microbiology and infectious disease 2005;51(1):31-7.
2005: DiPersio Joseph R; Deshpande Lalitagauri M; Biedenbach Douglas J; Toleman Mark A; Walsh Timothy R; Jones Ronald N
Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003).
Diagnostic microbiology and infectious disease 2005;51(1):1-7.
2005: Sader Helio S; Biedenbach Douglas J; Streit Jennifer M; Jones Ronald N
Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections.
International journal of antimicrobial agents 2005;25(1):89-92.
2005: Sader Helio S; Castanheira Mariana; Mendes Rodrigo E; Toleman Mark; Walsh Timothy R; Jones Ronald N
Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program.
International journal of antimicrobial agents 2005;25(1):57-61.
2005: Toleman Mark A; Biedenbach Doug; Bennett David M C; Jones Ronald N; Walsh Timothy R
Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme.
The Journal of antimicrobial chemotherapy 2005;55(1):61-70.
2004: Ross James E; Jones Ronald N;
MIC quality control guidelines for doxycycline when testing gram-positive control strains by the reference methods.
Diagnostic microbiology and infectious disease 2004;50(4):295-7.
2004: Messer Shawn A; Kirby Jeffrey T; Sader Helio S; Fritsche Thomas R; Jones Ronald N
Initial results from a longitudinal international surveillance programme for anidulafungin (2003).
The Journal of antimicrobial chemotherapy 2004;54(6):1051-6.
2004: Mendes Rodrigo E; Toleman Mark A; Ribeiro Julival; Sader Helio S; Jones Ronald N; Walsh Timothy R
Integron carrying a novel metallo-beta-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6')-30/aac(6')-Ib': report from the SENTRY Antimicrobial Surveillance Program.
Antimicrobial agents and chemotherapy 2004;48(12):4693-702.
2004: Castanheira Mariana; Toleman Mark A; Jones Ronald N; Schmidt Franz J; Walsh Timothy R
Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase.
Antimicrobial agents and chemotherapy 2004;48(12):4654-61.
2004: Fritsche Thomas R; Jones Ronald N
Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.
International journal of antimicrobial agents 2004;24(6):567-71.
2004: Ambrose P G; Bast D; Doern G V; Iannini P B; Jones R N; Klugman K P; Low D E
Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(10):1554-6; author reply 1556-7.
2004: Anderegg Tamara R; Jones Ronald N
Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2004;50(3):213-7.
2004: Sader Helio S; Streit Jennifer M; Fritsche Thomas R; Jones Ronald N
Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
Diagnostic microbiology and infectious disease 2004;50(3):201-4.
2004: Yu Wen-Liang; Winokur Patricia L; Jones Ronald N; Sader Hélio S
Surveillance in Taiwan using molecular epidemiology for extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2004;25(10):812-8.
2004: Pfaller M A; Espinel-Ingroff A; Jones R N
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
Journal of clinical microbiology 2004;42(10):4577-80.
2004: Deshpande Lalitagauri; Rhomberg Paul R; Fritsche Thomas R; Sader Helio S; Jones Ronald N
Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.
Diagnostic microbiology and infectious disease 2004;50(1):73-5.
2004: Biedenbach Douglas J; Moet Gary J; Jones Ronald N
Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
Diagnostic microbiology and infectious disease 2004;50(1):59-69.
2004: Fritsche T R; Moet G J; Jones R N
Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylase.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004;10(9):857-60.
2004: Tognim Maria Cristina Bronharo; Andrade Soraya Sgambatti; Silbert Suzane; Gales Ana Cristina; Jones Ronald N; Sader Hélio S
Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2004;8(5):284-91.
2004: Gales A C; Andrade S S; Sader H S; Jones R N
Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program.
Journal of chemotherapy (Florence, Italy) 2004;16(4):323-8.
2004: Jones Ronald N; Deshpande Lalitagauri M; Bell Jan M; Turnidge John D; Kohno Shigeru; Hirakata Yoichi; Ono Yasuo; Miyazawa Yukihisa; Kawakama Sayoko; Inoue Matsuhisa; Hirata Yasuyoshi; Toleman Mark A
Evaluation of the contemporary occurrence rates of metallo-beta-lactamases in multidrug-resistant Gram-negative bacilli in Japan: report from the SENTRY Antimicrobial Surveillance Program (1998-2002).
Diagnostic microbiology and infectious disease 2004;49(4):289-94.
2004: Sader Helio S; Streit Jennifer M; Fritsche Thomas R; Jones Ronald N
Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates.
Diagnostic microbiology and infectious disease 2004;49(4):283-7.
2004: Rhomberg Paul R; Jones Ronald N; Sader Helio S; Fritsche Thomas R;
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
Diagnostic microbiology and infectious disease 2004;49(4):273-81.
2004: Deshpande Lalitagauri M; Fritsche Thomas R; Jones Ronald N
Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2004;49(4):231-6.
2004: Goossens H; Malhotra-Kumar S; Eraksoy H; Unal S; Grabein B; Masterton R; Mendes C; Garcia-Rodriguez J-A; Russo G; Jones R N;
Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004;10(8):760-2.
2004: Streit Jennifer M; Jones Ronald N; Sader Helio S; Fritsche Thomas R
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
International journal of antimicrobial agents 2004;24(2):111-8.
2004: Jones Ronald N; Huynh Holly K; Biedenbach Douglas J
Activities of doripenem (S-4661) against drug-resistant clinical pathogens.
Antimicrobial agents and chemotherapy 2004;48(8):3136-40.
2004: Sader Helio S; Fedler Kelley A; Rennie Robert P; Stevens Shelley; Jones Ronald N
Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity.
Antimicrobial agents and chemotherapy 2004;48(8):3112-8.
2004: Jones Ronald N; Deshpande Lalitagauri; Fritsche Thomas R; Sader Helio S
Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003).
Diagnostic microbiology and infectious disease 2004;49(3):211-6.
2004: Fritsche Thomas R; Kirby Jeffrey T; Jones Ronald N
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Diagnostic microbiology and infectious disease 2004;49(3):201-9.
2004: Anderegg T R; Jones R N; Sader H S;
Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.
Journal of clinical microbiology 2004;42(7):3356-8.
2004: Castanheira M; Gales A C; Mendes R E; Jones R N; Sader H S
Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004;10(7):645-51.
2004: Jones Ronald N; Huynh Holly K; Biedenbach Douglas J; Fritsche Thomas R; Sader Helio S
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
The Journal of antimicrobial chemotherapy 2004;54(1):144-54.
2004: Jones Ronald N; Sader Helio S; Fritsche Thomas R
Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).
Diagnostic microbiology and infectious disease 2004;49(2):147-9.
2004: Ambrose Paul G; Anon Jack B; Owen Joel S; Van Wart Scott; McPhee Mary Eileen; Bhavnani Sujata M; Piedmonte Marion; Jones Ronald N
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(11):1513-20.
2004: Castanheira Mariana; Mendes Rodrigo E; Walsh Timothy R; Gales Ana C; Jones Ronald N
Emergence of the extended-spectrum beta-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: report from the SENTRY antimicrobial surveillance program.
Antimicrobial agents and chemotherapy 2004;48(6):2344-5.
2004: Christiansen K J; Bell J M; Turnidge J D; Jones R N
Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.
Antimicrobial agents and chemotherapy 2004;48(6):2049-55.
2004: Hurd H Scott; Doores Stephanie; Hayes Dermot; Mathew Alan; Maurer John; Silley Peter; Singer Randall S; Jones Ronald N
Public health consequences of macrolide use in food animals: a deterministic risk assessment.
Journal of food protection 2004;67(5):980-92.
2004: Jones Ronald N; Fritsche Thomas R; Sader Helio S
Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.
Diagnostic microbiology and infectious disease 2004;49(1):63-5.
2004: Jones Ronald N; Moet Gary J; Sader Helio S; Fritsche Thomas R
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
The Journal of antimicrobial chemotherapy 2004;53(5):804-7.
2004: Yu Wen-Liang; Chuang Yin-Ching; Jones Ronald N
A pragmatic approach to identify extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in Taiwan: in vitro activity of newer and established antimicrobial agents.
Diagnostic microbiology and infectious disease 2004;48(4):277-82.
2004: Mendes Rodrigo E; Castanheira Mariana; Garcia Patricia; Guzman Manuel; Toleman Mark A; Walsh Timothy R; Jones Ronald N;
First isolation of bla(VIM-2) in Latin America: report from the SENTRY Antimicrobial Surveillance Program.
Antimicrobial agents and chemotherapy 2004;48(4):1433-4.
2004: Streit Jennifer M; Jones Ronald N; Sader Helio S
Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
The Journal of antimicrobial chemotherapy 2004;53(4):669-74.
2004: Anderegg Tamara R; Fritsche Thomas R; Jones Ronald N;
Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide.
Journal of clinical microbiology 2004;42(3):1386-7.
2004: Patzer Jan; Toleman Mark A; Deshpande Lalitagauri M; Kaminska Wanda; Dzierzanowska Danuta; Bennett Peter M; Jones Ronald N; Walsh Timothy R
Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001).
The Journal of antimicrobial chemotherapy 2004;53(3):451-6.
2004: Sader Helio S; Jones Ronald N; Gales Ana C; Silva Juliana B; Pignatari Antonio C;
SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2004;8(1):25-79.
2004: Jones Ronald N; Streit Jennifer M; Fritsche Thomas R
Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.
International journal of antimicrobial agents 2004;23(2):197-9.
2004: Streit Jennifer M; Fritsche Thomas R; Sader Helio S; Jones Ronald N
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
Diagnostic microbiology and infectious disease 2004;48(2):137-43.
2004: Pfaller M A; Diekema D J; Messer S A; Boyken L; Hollis R J; Jones R N
In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.
Diagnostic microbiology and infectious disease 2004;48(2):101-5.
2004: Jones R N; Gordon K A; Biedenbach D J
Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study.
The Journal of antimicrobial chemotherapy 2004;53(2):258-65.
2004: Mutnick Alan H; Rhomberg Paul R; Sader Helio S; Jones Ronald N
Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
The Journal of antimicrobial chemotherapy 2004;53(2):290-6.
2004: Anderegg Tamara R; Jones Ronald N;
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.
Diagnostic microbiology and infectious disease 2004;48(1):55-7.
2004: Rhomberg Paul R; Jones Ronald N; Sader Helio S;
Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.
International journal of antimicrobial agents 2004;23(1):52-9.
2004: Anderegg Tamara R; Jones Ronald N
Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.
International journal of antimicrobial agents 2004;23(1):6-10.
2004: Kirby Jeffrey T; Sader Helio S; Walsh Timothy R; Jones Ronald N
Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).
Journal of clinical microbiology 2004;42(1):445-8.
2004: Yu Wen-Liang; Cheng Kuo-Chen; Wu Lii-Tzu; Pfaller Michael A; Winokur Patricia L; Jones Ronald N
Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan.
Antimicrobial agents and chemotherapy 2004;48(1):362-3.
2004: Jones Ronald N; Deshpande Lalitagauri M
Are Enterococcus faecalis strains with vat(E) in poultry a reservoir for human streptogramin resistance? vat(E) occurrence in human enterococcal bloodstream infections in North America (SENTRY Antimicrobial Surveillance Program, 2002).
Antimicrobial agents and chemotherapy 2004;48(1):360-1.
2004: Sader Helio S; Johnson David M; Jones Ronald N
In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.
Antimicrobial agents and chemotherapy 2004;48(1):53-62.
2004: Gales Ana Cristina; Pfaller Michael A; Sader Helio S; Hollis Richard J; Jones Ronald N
Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America.
Microbial drug resistance (Larchmont, N.Y.) 2004;10(4):286-91.
2004: McDermott P F; Bodeis S M; Aarestrup F M; Brown S; Traczewski M; Fedorka-Cray P; Wallace M; Critchley I A; Thornsberry C; Graff S; Flamm R; Beyer J; Shortridge D; Piddock L J; Ricci V; Johnson M M; Jones R N; Reller B; Mirrett S; Aldrobi J; Rennie R; Brosnikoff C; Turnbull L; Stein G; Schooley S; Hanson R A; Walker R D
Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.
Microbial drug resistance (Larchmont, N.Y.) 2004;10(2):124-31.
2003: Jones Ronald N; Sader Helio S; Beach Mondell L
Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).
International journal of antimicrobial agents 2003;22(6):551-6.
2003: Bell J M; Turnidge J D; Jones R N;
Prevalence of extended-spectrum beta-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001.
Antimicrobial agents and chemotherapy 2003;47(12):3989-93.
2003: Deshpande L M; Jones R N
Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(11):1120-4.
2003: Sader Helio S; Huynh Holly K; Jones Ronald N
Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.
Diagnostic microbiology and infectious disease 2003;47(3):547-50.
2003: Sader Helio S; Fritsche Thomas R; Mutnick Alan H; Jones Ronald N
Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002).
Diagnostic microbiology and infectious disease 2003;47(3):515-25.
2003: Biedenbach D J; Jones R N
Revision of linezolid disk diffusion quality control guidelines for testing Staphylococcus aureus ATCC 25923: an independent seven-laboratory trial.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(10):1035-7.
2003: Mendes Rodrigo E; Reis Adriana O; Gales Ana C; Jones Ronald N; Sader Hélio S
Ability of Latin America laboratories to detect antimicrobial resistance patterns: experience of the SENTRY Antimicrobial Surveillance Program (1997-2000).
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2003;7(5):282-9.
2003: Loza Elena; Cantón Rafael; Pascual Alvaro; Tubau Fe; Morosini M Isabel; Almaraz Felisa; Perea Evelio; Martín Rogelio; Jones Ronald N; Baquero Fernando
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)]
Enfermedades infecciosas y microbiología clínica 2003;21(8):404-9.
2003: Fritsche Thomas R; Sader Helio S; Jones Ronald N
Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002).
Diagnostic microbiology and infectious disease 2003;47(2):435-40.
2003: Stephen Jennifer M; Toleman Mark A; Walsh Timothy R; Jones Ronald N
Salmonella bloodstream infections: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).
International journal of antimicrobial agents 2003;22(4):395-405.
2003: Gordon Kelley A; Sader Helio S; Jones Ronald N
Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States.
Diagnostic microbiology and infectious disease 2003;47(1):377-83.
2003: Johnson D M; Sader H S; Fritsche T R; Biedenbach D J; Jones Ronald N
Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2003;47(1):373-6.
2003: Rhomberg Paul R; Jones Ronald N;
Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.
Diagnostic microbiology and infectious disease 2003;47(1):365-72.
2003: Sader Helio S; Biedenbach Douglas J; Jones Ronald N
Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001).
Diagnostic microbiology and infectious disease 2003;47(1):361-4.
2003: Deshpande L M; Beach M L; Mutnick A H; Jones R N
Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(8):893-6.
2003: Biedenbach Douglas J; Stephen Jennifer M; Jones Ronald N
Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program--North America, 2001.
Diagnostic microbiology and infectious disease 2003;46(4):291-4.
2003: Gordon Kelley A; Biedenbach Douglas J; Jones Ronald N
Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2003;46(4):285-9.
2003: Jones Ronald N; Deshpande Lalitagauri M
Distribution of fsr among Enterococcus faecalis isolates from the SENTRY antimicrobial surveillance program.
Journal of clinical microbiology 2003;41(8):4004-5.
2003: Gordon Kelley A; Rhomberg Paul R; Jones Ronald N
Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.
Journal of clinical microbiology 2003;41(8):3967-9.
2003: Diekema D J; Messer S A; Hollis R J; Jones R N; Pfaller M A
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
Journal of clinical microbiology 2003;41(8):3623-6.
2003: Bhavnani Sujata M; Hammel Jeffrey P; Forrest Alan; Jones Ronald N; Ambrose Paul G
Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(3):344-50.
2003: Jones Ronald N; Farrell David J; Morrissey Ian
Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.
Antimicrobial agents and chemotherapy 2003;47(8):2696-8.
2003: Jones R N; Pfaller M A;
Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(7):708-12.
2003: Deshpande Lalitagauri M; Jones Ronald N
Antagonism between penicillin and erythromycin against Streptococcus pneumoniae: does it exist?
Diagnostic microbiology and infectious disease 2003;46(3):223-5.
2003: Anderegg Tamara R; Biedenbach Douglas J; Jones Ronald N;
Quality control guidelines for MIC susceptibility testing of NVP PDF-713: a novel peptide deformylase inhibitor.
International journal of antimicrobial agents 2003;22(1):84-6.
2003: Andrade Soraya S; Jones Ronald N; Gales Ana C; Sader Helio S
Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001).
The Journal of antimicrobial chemotherapy 2003;52(1):140-1.
2003: Jones R N; Anderegg T R; Biedenbach D J
Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(6):543-6.
2003: Anderegg T R; Biedenbach D J; Jones R N;
Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2003;46(2):147-50.
2003: Anderegg Tamara R; Biedenbach Douglas J; Jones Ronald N;
Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.
Journal of clinical microbiology 2003;41(6):2795-6.
2003: Diekema Daniel J; Andrews Janet I; Huynh Holly; Rhomberg Paul R; Doktor Stella R; Beyer Jill; Shortridge Virginia D; Flamm Robert K; Jones Ronald N; Pfaller Michael A
Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci.
Journal of clinical microbiology 2003;41(6):2659-61.
2003: Anderegg Tamara R; Jones Ronald N;
Initial disk diffusion quality control guidelines for tylosin tested against Staphylococcus aureus ATCC 25923 and Streptococcus pneumoniae ATCC 49619.
International journal of antimicrobial agents 2003;21(6):594-6.
2003: Mutnick Alan H; Enne Victoria; Jones Ronald N
Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program.
The Annals of pharmacotherapy 2003;37(6):769-74.
2003: Jones Ronald N; Krisher Karen; Bird Deborah S;
Results of the survey of the quality assurance for commercially prepared microbiology media. Update from the College of American Pathologists Microbiology Surveys Program (2001).
Archives of pathology & laboratory medicine 2003;127(6):661-5.
2003: Jones Ronald N; Biedenbach Douglas J; Beach Mondell L
Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2003;46(1):77-80.
2003: Mutnick Alan H; Biedenbach Douglas J; Jones Ronald N
Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2003;46(1):63-8.
2003: Biedenbach Douglas J; Jones Ronald N
Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program.
Diagnostic microbiology and infectious disease 2003;46(1):55-61.
2003: Ambrose P G; Bhavnani S M; Jones R N
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
Antimicrobial agents and chemotherapy 2003;47(5):1643-6.
2003: Gordon Kelley A; Jones Ronald N;
Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000).
Diagnostic microbiology and infectious disease 2003;45(4):295-301.
2003: Rennie Robert P; Jones Ronald N; Mutnick Alan H;
Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000).
Diagnostic microbiology and infectious disease 2003;45(4):287-93.
2003: Hoban Daryl J; Biedenbach Douglas J; Mutnick Alan H; Jones Ronald N
Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000).
Diagnostic microbiology and infectious disease 2003;45(4):279-85.
2003: Jones Ronald N; Biedenbach Douglas J
Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
Diagnostic microbiology and infectious disease 2003;45(4):273-8.
2003: Yu Wen-Liang; Wu Lii-Tzu; Pfaller Michael A; Winokur Patricia L; Jones Ronald N
Confirmation of extended-spectrum beta-lactamase-producing Serratia marcescens: preliminary report from Taiwan.
Diagnostic microbiology and infectious disease 2003;45(4):221-4.
2003: Pfaller M A; Diekema D J; Messer S A; Hollis R J; Jones R N
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
Antimicrobial agents and chemotherapy 2003;47(3):1068-71.
2003: Jones Ronald N
Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001).
Seminars in respiratory and critical care medicine 2003;24(1):121-34.
2003: Tzouvelekis L S; Lukova V; Tassios P T; Fluit A C; Jones R N; Legakis N J
Resistance to beta-lactams among blood isolates of Salmonella spp. in European hospitals: results from the SENTRY Antimicrobial Surveillance Program 1997-98.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(2):149-52.
2003: Bell Jan M; Turnidge John D; Ballow Charles H; Jones Ronald N;
Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.
The Journal of antimicrobial chemotherapy 2003;51(2):339-45.
2003: Gales Ana C; Tognim Maria C B; Reis Adriana O; Jones Ronald N; Sader Hélio S
Emergence of an IMP-like metallo-enzyme in an Acinetobacter baumannii clinical strain from a Brazilian teaching hospital.
Diagnostic microbiology and infectious disease 2003;45(1):77-9.
2003: Anderegg Tamara R; Jones Ronald N;
Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone.
Diagnostic microbiology and infectious disease 2003;45(1):73-6.
2003: Yamazumi T; Pfaller M A; Messer S A; Houston A K; Boyken L; Hollis R J; Furuta I; Jones R N
Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.
Journal of clinical microbiology 2003;41(1):267-72.
2003: Pfaller M A; Diekema D J; Messer S A; Boyken L; Hollis R J; Jones R N;
In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.
Journal of clinical microbiology 2003;41(1):78-83.
2003: Jones Ronald N; Biedenbach Douglas J; Gales Ana C
Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).
International journal of antimicrobial agents 2003;21(1):1-7.
2003: Mutnick Alan H; Kirby Jeffrey T; Jones Ronald N;
CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance.
The Annals of pharmacotherapy 2003;37(1):47-56.
2003: Jones Ronald N; Rubino Christopher M; Bhavnani Sujata M; Ambrose Paul G;
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
Antimicrobial agents and chemotherapy 2003;47(1):292-6.
2003: Jones Ronald N; Rhomberg Paul R
Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor.
The Journal of antimicrobial chemotherapy 2003;51(1):157-61.
2003: Castanheira Mariana; Jones Ronald N; Silbert Suzane; Brandileone Maria C C; Sader Hélio S
Typing and molecular characterization of Streptococcus pneumoniae with reduced susceptibility to cefotaxime isolated in Latin America.
Microbial drug resistance (Larchmont, N.Y.) 2003;9(4):345-51.
2002: Jones Ronald N; Varnam David J
Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Diagnostic microbiology and infectious disease 2002;44(4):379-82.
2002: Mathai Dilip; Rhomberg Paul R; Biedenbach Douglas J; Jones Ronald N;
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories.
Diagnostic microbiology and infectious disease 2002;44(4):367-77.
2002: Bolmstrom A; Ballow C H; Qwarnstrom A; Biedenbach D J; Jones R N
Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002;8(12):791-800.
2002: Jones Ronald N; Deshpande Lalitagauri M; Mutnick Alan H; Biedenbach Douglas J
In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
The Journal of antimicrobial chemotherapy 2002;50(6):915-32.
2002: Jones Ronald N; Rhomberg Paul R; Varnam David J; Mathai Dilip
A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India.
International journal of antimicrobial agents 2002;20(6):426-31.
2002: Diekema D J; Pfaller M A; Jones R N;
Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000.
International journal of antimicrobial agents 2002;20(6):412-8.
2002: Yu W-L; Jones R N; Hollis R J; Messer S A; Biedenbach D J; Deshpande L M; Pfaller M A
Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.
Journal of clinical microbiology 2002;40(12):4666-9.
2002: Gales Ana C; Sader Helio S; Mendes Rodrigo E; Jones Ronald N
Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2002;44(3):313-8.
2002: Gales Ana C; Sader H Hélio S; Jones Ronald N
Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2002;44(3):301-11.
2002: Gales Ana C; Sader Helio S; Jones Ronald N;
Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000).
Diagnostic microbiology and infectious disease 2002;44(3):289-99.
2002: Sader Helio S; Jones Ronald N; Silva Juliana B;
Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns.
Diagnostic microbiology and infectious disease 2002;44(3):281-8.
2002: Sader Helio S; Jones Ronald N; Andrade-Baiocchi Soraya; Biedenbach Douglas J;
Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers.
Diagnostic microbiology and infectious disease 2002;44(3):273-80.
2002: Jones Ronald N
Microbiology of newer fluoroquinolones: focus on respiratory pathogens.
Diagnostic microbiology and infectious disease 2002;44(3):213-20.
2002: Jones Ronald N; Mutnick Alan H; Varnam David J
Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY antimicrobial surveillance program (1997 to 2001).
Journal of clinical microbiology 2002;40(11):4332-3.
2002: Jones Ronald N; Cullen Sharon
Re-evaluations of disk diffusion quality control ranges for 11 drugs: report from the QC working group of the national committee for clinical laboratory standards.
International journal of antimicrobial agents 2002;20(4):289-92.
2002: Mandell Lionel A; Jones Ronald N
Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.
Diagnostic microbiology and infectious disease 2002;44(1):127-8.
2002: Nicholson Susan C; Webb C Douglas; Andriole Vincent T; Jones Ronald N; Wilson Walter R
Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
Diagnostic microbiology and infectious disease 2002;44(1):101-7.
2002: Jones Ronald N; Andes David R; Mandell Lionel A; Gothelf Samantha; Ehrhardt Anton F; Nicholson Susan C
Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 2002;44(1):93-100.
2002: Pfaller Michael A; Jones Ronald N
Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Diagnostic microbiology and infectious disease 2002;44(1):77-84.
2002: Jones Ronald N; Mandell Lionel A
Fluoroquinolones for the treatment of outpatient community-acquired pneumonia.
Diagnostic microbiology and infectious disease 2002;44(1):69-76.
2002: Biedenbach Douglas J; Jones Ronald N
Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin.
Diagnostic microbiology and infectious disease 2002;43(4):323-6.
2002: Bell Jan M; Turnidge John D; Pfaller Michael A; Jones Ronald N
In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
Diagnostic microbiology and infectious disease 2002;43(4):315-8.
2002: Kirby Jeffrey T; Mutnick Alan H; Jones Ronald N; Biedenbach Douglas J; Pfaller Michael A
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
Diagnostic microbiology and infectious disease 2002;43(4):303-9.
2002: Anderegg Tamara R; Biedenbach Douglas J; Jones Ronald N
In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
Antimicrobial agents and chemotherapy 2002;46(8):2662-4.
2002: Turnidge John; Bell Jan; Biedenbach Douglas J; Jones Ronald N
Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999.
International journal of antimicrobial agents 2002;20(1):10-7.
2002: Jones Ronald N; Kirby Jeffrey T; Beach Mondell L; Biedenbach Douglas J; Pfaller Michael A
Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2002;43(3):239-43.
2002: Ballow Charles H; Biedenbach Douglas J; Rossi Flavia; Jones Ronald N;
Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS).
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2002;6(3):100-9.
2002: Mutnick A H; Turner P J; Jones R N
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Journal of chemotherapy (Florence, Italy) 2002;14(3):253-8.
2002: Gordon Kelley A; Beach Mondell L; Biedenbach Douglas J; Jones Ronald N; Rhomberg Paul R; Mutnick Alan H
Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000).
Diagnostic microbiology and infectious disease 2002;43(2):157-62.
2002: Howard W; Biedenbach D J; Jones R N
Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002;8(6):340-4.
2002: Anderegg Tamara R; Biedenbach Douglas J; Jones Ronald N
In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci.
The Journal of antimicrobial chemotherapy 2002;49(6):1019-21.
2002: Pfaller M A; Messer S A; Hollis R J; Jones R N; Diekema D J
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
Antimicrobial agents and chemotherapy 2002;46(6):1723-7.
2002: Jones R N; Anderegg T R; Deshpande L M
AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.
Diagnostic microbiology and infectious disease 2002;43(1):87-90.
2002: Ballow Charles H; Jones Ronald N; Biedenbach Douglas J;
A multicenter evaluation of linezolid antimicrobial activity in North America.
Diagnostic microbiology and infectious disease 2002;43(1):75-83.
2002: Mutnick Alan H; Biedenbach Douglas J; Turnidge John D; Jones Ronald N
Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
Diagnostic microbiology and infectious disease 2002;43(1):65-73.
2002: Johnson David M; Biedenbach Douglas J; Jones Ronald N
Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
Diagnostic microbiology and infectious disease 2002;43(1):49-60.
2002: Pfaller Michael A; Jones Ronald N;
Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000.
International journal of antimicrobial agents 2002;19(5):383-8.
2002: Gordon Kelley A; Pfaller Michael A; Jones Ronald N;
BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).
The Journal of antimicrobial chemotherapy 2002;49(5):851-5.
2002: Yu Wen Liang; Pfaller Michael A; Winokur Patricia L; Jones Ronald N
Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan.
Emerging infectious diseases 2002;8(5):522-4.
2002: Deshpande L M; Fix A M; Pfaller M A; Jones R N;
Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods.
Diagnostic microbiology and infectious disease 2002;42(4):283-90.
2002: Yu Wen Liang; Winokur Patricia L; Von Stein Diana L; Pfaller Michael A; Wang Jen Hsien; Jones Ronald N
First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan.
Antimicrobial agents and chemotherapy 2002;46(4):1098-100.
2002: Pfaller M A; Messer S A; Hollis R J; Jones R N;
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Antimicrobial agents and chemotherapy 2002;46(4):1032-7.
2002: Jones Ronald N; Pfaller Michael A
Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?
Diagnostic microbiology and infectious disease 2002;42(3):213-5.
2002: Bell Jan M; Turnidge John D; Gales Ana C; Pfaller Michael A; Jones Ronald N;
Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99).
Diagnostic microbiology and infectious disease 2002;42(3):193-8.
2002: Bhavnani Sujata M; Ambrose Paul G; Jones Ronald N
Pharmacodynamics in the evaluation of drug regimens.
The Annals of pharmacotherapy 2002;36(3):530-2.
2002: Pfaller M A; Diekema D J; Jones R N; Messer S A; Hollis R J;
Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.
Journal of clinical microbiology 2002;40(3):852-6.
2002: Ambrose Paul G; Owens Robert C; Garvey Michael J; Jones Ronald N
Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime.
The Journal of antimicrobial chemotherapy 2002;49(3):445-53.
2002: Garcia-Rodriguez J A; Jones R N;
Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme.
Journal of chemotherapy (Florence, Italy) 2002;14(1):25-32.
2002: Pfaller M A; Beach M L; Gordon K A; Jones R N
Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons.
Journal of chemotherapy (Florence, Italy) 2002;14(1):13-8.
2002: Rhomberg Paul R; Jones Ronald N
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum.
Diagnostic microbiology and infectious disease 2002;42(2):145-7.
2002: Jones Ronald N; Della-Latta Phyllis; Lee Lillian V; Biedenbach Douglas J
Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 2002;42(2):137-9.
2002: Jones Ronald N; Biedenbach Douglas J; Anderegg Tamara R
In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.
Diagnostic microbiology and infectious disease 2002;42(2):119-22.
2002: Bell J M; Turnidge J D; Jones R N;
Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: report from the SENTRY antimicrobial surveillance program, (1998-1999) including an in vitro evaluation of BMS284756.
International journal of antimicrobial agents 2002;19(2):125-32.
2002: Jones Ronald N; Pfaller Michael A; Rhomberg Paul R; Walter Donald H
Tiamulin activity against fastidious and nonfastidious veterinary and human bacterial isolates: initial development of in vitro susceptibility test methods.
Journal of clinical microbiology 2002;40(2):461-5.
2002: Cereda Rosangela F; Gales Ana C; Silbert Suzane; Jones Ronald N; Sader Helio S
Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2002;23(1):19-22.
2001: Biedenbach D J; Jones R N;
Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains.
Diagnostic microbiology and infectious disease 2001;41(4):225-8.
2001: Pfaller M A; Jones R N; Biedenbach D J;
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).
Diagnostic microbiology and infectious disease 2001;41(4):177-82.
2001: Jones R N; Masterton R
Determining the value of antimicrobial surveillance programs.
Diagnostic microbiology and infectious disease 2001;41(4):171-5.
2001: Jones R N
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001.
Diagnostic microbiology and infectious disease 2001;41(4):169, 197-8.
2001: Pfaller M A; Ehrhardt A F; Jones R N
Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
The American journal of medicine 2001;111 Suppl 9A():4S-12S; discussion 36S-38S.
2001: Diekema D J; Jones R N
Oxazolidinone antibiotics.
Lancet 2001;358(9297):1975-82.
2001: Pfaller M A; Messer S A; Mills K; Bolmström A; Jones R N
Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.
Journal of clinical microbiology 2001;39(12):4387-9.
2001: McDermott P F; Barry A L; Jones R N; Stein G E; Thornsberry C; Wu C C; Walker R D
Standardization of broth microdilution and disk diffusion susceptibility tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: quality control standards for ceftiofur, enrofloxacin, florfenicol, gentamicin, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole.
Journal of clinical microbiology 2001;39(12):4283-7.
2001: Gordon K A; Fusco J; Biedenbach D J; Pfaller M A; Jones R N
Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program.
Antimicrobial agents and chemotherapy 2001;45(12):3599-600.
2001: Jones R N; Beach M L; Pfaller M A
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Diagnostic microbiology and infectious disease 2001;41(3):161-3.
2001: Deshpande L; Biedenbach D J; Jones R N
Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods.
International journal of antimicrobial agents 2001;18(5):437-40.
2001: Pfaller M A; Messer S A; Mills K; Bolmström A; Jones R N
Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.
Journal of clinical microbiology 2001;39(11):3952-4.
2001: Jones R N
Prediction of enterococcal imipenem susceptibility using ampicillin or penicillin MICs: more evidence for a class concept.
Journal of clinical microbiology 2001;39(10):3810-1.
2001: Yamazumi T; Furuta I; Diekema D J; Pfaller M A; Jones R N
Comparison of the Vitek gram-positive susceptibility 106 card, the MRSA-Screen latex agglutination test, and mecA analysis for detecting oxacillin resistance in a geographically diverse collection of clinical isolates of coagulase-negative staphylococci.
Journal of clinical microbiology 2001;39(10):3633-6.
2001: Jones R N;
Method preferences and test accuracy of antimicrobial susceptibility testing: updates from the College of Amercian Pathologists Microbiology Surveys Program.
Archives of pathology & laboratory medicine 2001;125(10):1285-9.
2001: Pfaller M A; Messer S A; Hollis R J; Jones R N
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Antimicrobial agents and chemotherapy 2001;45(10):2862-4.
2001: Richter S S; Gordon K A; Rhomberg P R; Pfaller M A; Jones R N
Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99.
Diagnostic microbiology and infectious disease 2001;41(1-2):83-8.
2001: Jones R N; Pfaller M A; Jacobs M R; Appelbaum P C; Fuchs P C
Cefditoren in vitro activity and spectrum: a review of international studies using reference methods.
Diagnostic microbiology and infectious disease 2001;41(1-2):1-14.
2001: Pfaller M A; Diekema D J; Jones R N; Sader H S; Fluit A C; Hollis R J; Messer S A;
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.
Journal of clinical microbiology 2001;39(9):3254-9.
2001: Sader H S; Gales A C; Pfaller M A; Mendes R E; Zoccoli C; Barth A; Jones R N
Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2001;5(4):200-14.
2001: Sader H S; Gales A C; Jones R N
Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2001;5(4):171-6.
2001: Jones R N
In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains.
Journal of chemotherapy (Florence, Italy) 2001;13(4):363-76.
2001: Biedenbach D J; Beach M L; Jones R N
In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Diagnostic microbiology and infectious disease 2001;40(4):173-7.
2001: Shen D; Winokur P; Jones R N
Characterization of extended spectrum beta-lactamase-producing Klebsiella pneumoniae from Beijing, China.
International journal of antimicrobial agents 2001;18(2):185-8.
2001: Fix A M; Pfaller M A; Biedenbach D J; Beach M L; Jones R N
Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development.
International journal of antimicrobial agents 2001;18(2):141-5.
2001: Mathai D; Jones R N; Pfaller M A;
Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).
Diagnostic microbiology and infectious disease 2001;40(3):129-36.
2001: Deshpande L M; Gales A C; Jones R N
GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria.
International journal of antimicrobial agents 2001;18(1):29-35.
2001: Jones R N; Biedenbach D J; Johnson D M; Pfaller M A
In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent.
Journal of chemotherapy (Florence, Italy) 2001;13(3):244-54.
2001: Rospide M F; Biedenbach D J; Jones R N
Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae.
International journal of antimicrobial agents 2001;17(6):451-5.
2001: Jones R N
Conventional dogma applied to quinolones? Time for a change.
The Journal of antimicrobial chemotherapy 2001;47(6):893.
2001: Jones R N; Biedenbach D J;
Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001).
Diagnostic microbiology and infectious disease 2001;40(1-2):71-3.
2001: Pfaller M A; Jones R N; Walter D H;
Proposed quality control guidelines for National Committee for Clinical Laboratory Standards Susceptibility Tests using the veterinary antimicrobial agent tiamulin.
Diagnostic microbiology and infectious disease 2001;40(1-2):67-70.
2001: Jones R N; Ballow C H; Biedenbach D J;
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
Diagnostic microbiology and infectious disease 2001;40(1-2):59-66.
2001: Rhomberg P R; Biedenbach D J; Jones R N
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
Diagnostic microbiology and infectious disease 2001;40(1-2):45-9.
2001: Pfaller M A; Acar J; Jones R N; Verhoef J; Turnidge J; Sader H S
Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 2():S156-67.
2001: Gales A C; Jones R N; Turnidge J; Rennie R; Ramphal R
Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 2():S146-55.
2001: Low D E; Keller N; Barth A; Jones R N
Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 2():S133-45.
2001: Diekema D J; Pfaller M A; Schmitz F J; Smayevsky J; Bell J; Jones R N; Beach M;
Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 2():S114-32.
2001: Gales A C; Jones R N; Forward K R; Liñares J; Sader H S; Verhoef J
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 2():S104-13.
2001: Hoban D J; Doern G V; Fluit A C; Roussel-Delvallez M; Jones R N
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32 Suppl 2():S81-93.
2001: Gales A; Sader H; Jones R N;
Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
Antimicrobial agents and chemotherapy 2001;45(5):1463-6.
2001: Deshpande L M; Jones R N; Pfaller M A;
Accuracy of broth microdilution and E test methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999).
Diagnostic microbiology and infectious disease 2001;39(4):267-9.
2001: Biedenbach D J; Jones R N; Pfaller M A;
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Diagnostic microbiology and infectious disease 2001;39(4):245-50.
2001: Jones R N; Pfaller M A;
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
Diagnostic microbiology and infectious disease 2001;39(4):237-43.
2001: Diekema D J; Beach M L; Pfaller M A; Jones R N;
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2001;7(3):152-7.
2001: Pfaller M A; Jones R N
Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999.
Postgraduate medicine 2001;109(2 Suppl):10-21.
2001: Sader H S; Jones R N; Ballow C H; Biedenbach D J; Cered R F;
Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2001;5(1):21-31.
2001: Jones R N; Pfaller M A; Stilwell M;
Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
Diagnostic microbiology and infectious disease 2001;39(2):133-5.
2001: Erwin M E; Fix A M; Jones R N
Three independent yearly analyses of the spectrum and potency of metronidazole: a multicenter study of 1,108 contemporary anaerobic clinical isolates.
Diagnostic microbiology and infectious disease 2001;39(2):129-32.
2001: Gales A C; Biedenbach D J; Winokur P; Hacek D M; Pfaller M A; Jones R N
Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme.
Diagnostic microbiology and infectious disease 2001;39(2):125-7.
2001: Mathai D; Lewis M T; Kugler K C; Pfaller M A; Jones R N;
Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998).
Diagnostic microbiology and infectious disease 2001;39(2):105-16.
2001: Jones R N
Resistance patterns among nosocomial pathogens: trends over the past few years.
Chest 2001;119(2 Suppl):397S-404S.
2001: Biedenbach D J; Jones R N
In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods.
Diagnostic microbiology and infectious disease 2001;39(1):49-53.
2001: Jones R N; Hare R S; Sabatelli F J;
In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial.
The Journal of antimicrobial chemotherapy 2001;47(1):15-25.
2001: Gales A C; Reis A O; Jones R N
Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
Journal of clinical microbiology 2001;39(1):183-90.
2001: Yamazumi T; Marshall S A; Wilke W W; Diekema D J; Pfaller M A; Jones R N
Comparison of the Vitek Gram-Positive Susceptibility 106 card and the MRSA-screen latex agglutination test for determining oxacillin resistance in clinical bloodstream isolates of Staphylococcus aureus.
Journal of clinical microbiology 2001;39(1):53-6.
2000: Jones R N; Pfaller M A
Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).
Journal of clinical microbiology 2000;38(11):4298-9.
2000: Jones R N; Pfaller M A
Potencies of newer fluoroquinolones against Viridans group Streptococciisolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada!
Antimicrobial agents and chemotherapy 2000;44(10):2922-3.
2000: Sader H S; Gales A C; Granacher T D; Pfaller M A; Jones R N;
Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2000;4(5):245-54.
2000: Andrews J I; Diekema D J; Hunter S K; Rhomberg P R; Pfaller M A; Jones R N; Doern G V
Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere.
American journal of obstetrics and gynecology 2000;183(4):859-62.
2000: Pfaller M A; Messer S A; Houston A; Mills K; Bolmstrom A; Jones R N
Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.
Journal of clinical microbiology 2000;38(10):3715-7.
2000: Yamazumi T; Pfaller M A; Messer S A; Houston A; Hollis R J; Jones R N
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.
Antimicrobial agents and chemotherapy 2000;44(10):2883-6.
2000: Pfaller M A; Jones R N
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
The Journal of antimicrobial chemotherapy 2000;46 Suppl T2():25-37.
2000: Jones R N
Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection.
The Journal of antimicrobial chemotherapy 2000;46 Suppl T2():1-8.
2000: Wisplinghoff H; Edmond M B; Pfaller M A; Jones R N; Wenzel R P; Seifert H
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31(3):690-7.
2000: Jones R N; Pfaller M A
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;31 Suppl 2():S16-23.
2000: Marshall S A; Kugler K C; Jones R N
Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media.
International journal of antimicrobial agents 2000;15(4):291-7.
2000: Deshpande L; Pfaller M A; Jones R N
In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum beta-lactamase producing strains.
International journal of antimicrobial agents 2000;15(4):271-5.
2000: Jones R N; Pfaller M A; Erwin M E
Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas.
International journal of antimicrobial agents 2000;15(3):227-30.
2000: Jones R N; Erwin M E
Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 2000;37(3):195-201.
2000: Jones R N; Jenkins S G; Hoban D J; Pfaller M A; Ramphal R
In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
International journal of antimicrobial agents 2000;15(2):111-8.
2000: Marshall S A; Erwin M E; Jones R N
Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent. Quality Control Study Group.
Journal of clinical microbiology 2000;38(6):2462-3.
2000: Jones R N; Biedenbach D J; Johnson D M
Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods.
Diagnostic microbiology and infectious disease 2000;37(2):143-6.
2000: Deshpande L M; Jones R N
Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).
Diagnostic microbiology and infectious disease 2000;37(2):139-42.
2000: Jones R N; Croco M A; Kugler K C; Pfaller M A; Beach M L
Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997).
Diagnostic microbiology and infectious disease 2000;37(2):115-25.
2000: Johnson D M; Biedenbach D J; Beach M L; Pfaller M A; Jones R N
Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
Diagnostic microbiology and infectious disease 2000;37(2):99-105.
2000: Jones R N; Jenkins S G; Hoban D J; Pfaller M A; Ramphal R
In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
Diagnostic microbiology and infectious disease 2000;37(2):93-8.
2000: Lewis M T; Gales A C; Sader H S; Pfaller M A; Jones R N
Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from latin american patients with a diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998).
Diagnostic microbiology and infectious disease 2000;37(1):63-74.
2000: Lewis R E; Klepser M E; Ernst E J; Snabes M A; Jones R N
Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection.
Diagnostic microbiology and infectious disease 2000;37(1):51-5.
2000: Jones R N; Deshpande L M; Erwin M E; Barrett M S; Beach M L
Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods.
The Journal of antimicrobial chemotherapy 2000;45 Suppl 1():67-70.
2000: Kugler K C; Denys G A; Wilson M L; Jones R N
Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): case reports from the SENTRY antimicrobial surveillance program.
Diagnostic microbiology and infectious disease 2000;36(4):269-72.
2000: Biedenbach D J; Jones R N
Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).
Diagnostic microbiology and infectious disease 2000;36(4):255-9.
2000: Bhavnani S M; Drake J A; Forrest A; Deinhart J A; Jones R N; Biedenbach D J; Ballow C H
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.
Diagnostic microbiology and infectious disease 2000;36(3):145-58.
2000: Gales A C; Jones R N; Gordon K A; Sader H S; Wilke W W; Beach M L; Pfaller M A; Doern G V
Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).
The Journal of antimicrobial chemotherapy 2000;45(3):295-303.
2000: Pfaller M A; Mujeeb I; Hollis R J; Jones R N; Doern G V
Evaluation of the discriminatory powers of the Dienes test and ribotyping as typing methods for Proteus mirabilis.
Journal of clinical microbiology 2000;38(3):1077-80.
2000: Pfaller M A; Jones R N; Doern G V; Sader H S; Messer S A; Houston A; Coffman S; Hollis R J
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.
Antimicrobial agents and chemotherapy 2000;44(3):747-51.
2000: Winokur P L; Eidelstain M V; Stetsiouk O; Stratchounski L; Blahova J; Reshedko G K; Croco M A; Hollis R J; Pfaller M A; Jones R N
Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2000;6(2):103-8.
2000: Jones R N
Perspectives on the development of new antimicrobial agents for resistant gram-positive pathogens.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2000;4(1):1-8.
2000: Lewis M T; Jones R N
Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against streptococcus pneumoniae and enterococci isolates from the western hemisphere: example of international surveillance (SENTRY antimicrobial surveillance program )in the development of new drugs.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2000;4(1):15-21.
2000: Diekema D J; Pfaller M A; Jones R N; Doern G V; Kugler K C; Beach M L; Sader H S
Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.
International journal of antimicrobial agents 2000;13(4):257-71.
2000: Ramphal R; Hoban D J; Pfaller M A; Jones R N
Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
Diagnostic microbiology and infectious disease 2000;36(2):125-9.
2000: Putnam S D; Gray G C; Biedenbach D J; Jones R N
Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2000;6(1):2-8.
2000: Gales A C; Gordon K A; Wilke W W; Pfaller M A; Jones R N
Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.
Diagnostic microbiology and infectious disease 2000;36(1):61-4.
2000: Gales A C; Jones R N
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Diagnostic microbiology and infectious disease 2000;36(1):19-36.
2000: Diekema D I; Jones R N
Oxazolidinones: a review.
Drugs 2000;59(1):7-16.
2000: Odland B A; Erwin M E; Jones R N
Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications.
Journal of clinical microbiology 2000;38(1):453-5.
2000: Diekema D J; Pfaller M A; Turnidge J; Verhoef J; Bell J; Fluit A C; Doern G V; Jones R N;
Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance Centers worldwide, 1998.
Microbial drug resistance (Larchmont, N.Y.) 2000;6(3):213-21.
2000: Gales A C; Jones R N; Pfaller M A; Gordon K A; Sader H S
Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTRY Study Group.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2000;4(2):75-84.
1999: Jones R N
Summation: beta-lactam resistance surveillance in the Asia-Western Pacific region.
Diagnostic microbiology and infectious disease 1999;35(4):333-8.
1999: Biedenbach D J; Johnson D M; Jones R N
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):325-31.
1999: Lewis M T; Biedenbach D J; Jones R N
In vitro evaluation of broad-spectrum beta-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):317-23.
1999: Lewis M T; Yamaguchi K; Biedenbach D J; Jones R N
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):307-15.
1999: Biedenbach D J; Johnson D M; Jones R N
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):299-305.
1999: Johnson D M; Biedenbach D J; Jones R N
In vitro evaluation of broad-spectrum beta-lactams in the philippines medical centers: role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):291-7.
1999: Lewis M T; Biedenbach D J; Jones R N
In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):285-90.
1999: Biedenbach D J; Lewis M T; Jones R N
In vitro evaluation of cefepime and other broad-spectrum beta-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(4):277-83.
1999: Tenover F C; Jones R N; Swenson J M; Zimmer B; McAllister S; Jorgensen J H
Methods for improved detection of oxacillin resistance in coagulase-negative staphylococci: results of a multicenter study.
Journal of clinical microbiology 1999;37(12):4051-8.
1999: Jones R N
Disk diffusion susceptibility test development for the new glycylcycline, GAR-936.
Diagnostic microbiology and infectious disease 1999;35(3):249-52.
1999: Pfaller M A; Jones R N; Doern G V; Salazar J C
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(3):235-41.
1999: Jones R N; Erwin M E; Biedenbach D J; Johnson D M; Pfaller M A
Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
Diagnostic microbiology and infectious disease 1999;35(3):227-34.
1999: Jones R N
The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1999;56(22 Suppl 3):S4-11.
1999: Pfaller M A; Jones R N; Doern G V
Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela: comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(2):153-8.
1999: Xu Y; Chen M; Biedenbach D J; Deshpande L M; Jones R N
Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(2):135-42.
1999: Diekema D J; Pfaller M A; Jones R N; Doern G V; Winokur P L; Gales A C; Sader H S; Kugler K; Beach M
Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(3):595-607.
1999: Jones R N
Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(3):495-502.
1999: Buschelman B; Jones R N; Pfaller M A; Koontz F P; Doern G V
Colony morphology of Candida spp. as a guide to species identification.
Diagnostic microbiology and infectious disease 1999;35(1):89-91.
1999: Deshpande L M; Diekema D J; Jones R N
Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.
Diagnostic microbiology and infectious disease 1999;35(1):81-8.
1999: Pfaller M A; Korten V; Jones R N; Doern G V
Multicenter evaluation of the antimicrobial activity for seven broad-spectrum beta-lactams in Turkey using the Etest method. Turkish Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;35(1):65-73.
1999: Jones R N; Kugler K C; Pfaller M A; Winokur P L
Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997.
Diagnostic microbiology and infectious disease 1999;35(1):55-63.
1999: Pfaller M A; Jones R N; Doern G V; Fluit A C; Verhoef J; Sader H S; Messer S A; Houston A; Coffman S; Hollis R J
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).
Diagnostic microbiology and infectious disease 1999;35(1):19-25.
1999: Diekema D J; Pfaller M A; Messer S A; Houston A; Hollis R J; Doern G V; Jones R N
In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.
Antimicrobial agents and chemotherapy 1999;43(9):2236-9.
1999: Edmond M B; Wallace S E; McClish D K; Pfaller M A; Jones R N; Wenzel R P
Nosocomial bloodstream infections in United States hospitals: a three-year analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(2):239-44.
1999: Odland B A; Jones R N; Verhoef J; Fluit A; Beach M L
Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).
Diagnostic microbiology and infectious disease 1999;34(4):315-20.
1999: Lewis R E; Klepser M E; Ernst E J; Lund B C; Biedenbach D J; Jones R N
Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection.
Antimicrobial agents and chemotherapy 1999;43(8):2005-9.
1999: Willey B M; Jones R N; McGeer A; Witte W; French G; Roberts R B; Jenkins S G; Nadler H; Low D E
Practical approach to the identification of clinically relevant Enterococcus species.
Diagnostic microbiology and infectious disease 1999;34(3):165-71.
1999: Shen D; Biedenbach D J; Winokur P L; Pfaller M A; Jones R N
Phenotypic and genotypic characterizations of Chinese strains of Escherichia coli producing extended-spectrum beta-lactamases.
Diagnostic microbiology and infectious disease 1999;34(3):159-64.
1999: Biedenbach D J; Croco M A; Barrett T J; Jones R N
Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1999;18(6):428-31.
1999: Marshall S A; Pfaller M A; Jones R N
Ability of the modified Vitek card to detect coagulase-negative staphylococcal with mecA and Oxacillin-resistant phenotypes.
Journal of clinical microbiology 1999;37(6):2122-3.
1999: Yamaguchi K; Mathai D; Biedenbach D J; Lewis M T; Gales A C; Jones R N
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):123-34.
1999: Jones R N; Marshall S A; Erwin M E
Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):103-10.
1999: Hayward C L; Erwin M E; Barrett M S; Jones R N
Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates.
Diagnostic microbiology and infectious disease 1999;34(2):99-102.
1999: Jones R N; Johnson D M; Erwin M E; Beach M L; Biedenbach D J; Pfaller M A
Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;34(2):91-8.
1999: Jones R N; Biedenbach D J; Erwin M E; Beach M L; Pfaller M A
Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
Journal of clinical microbiology 1999;37(6):1999-2002.
1999: Kugler K C; Biedenbach D J; Jones R N
Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms.
Diagnostic microbiology and infectious disease 1999;34(1):73-6.
1999: Doern G V; Jones R N; Pfaller M A; Kugler K C; Beach M L
Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America).
Diagnostic microbiology and infectious disease 1999;34(1):65-72.
1999: Diekema D J; Jones R N; Rolston K V
Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers.
Diagnostic microbiology and infectious disease 1999;34(1):37-43.
1999: Seguin J C; Walker R D; Caron J P; Kloos W E; George C G; Hollis R J; Jones R N; Pfaller M A
Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: potential human-to-animal transmission.
Journal of clinical microbiology 1999;37(5):1459-63.
1999: Doern G V; Brueggemann A B; Pfaller M A; Jones R N
Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: a report from the College of American Pathologists Microbiology Proficiency Survey Program.
Archives of pathology & laboratory medicine 1999;123(4):285-9.
1999: Biedenbach D J; Marshall S A; Jones R N
Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System.
Diagnostic microbiology and infectious disease 1999;33(4):305-7.
1999: Pfaller M A; Jones R N; Doern G V; Sader H S; Kugler K C; Beach M L
Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.
Diagnostic microbiology and infectious disease 1999;33(4):283-97.
1999: Biedenbach D J; Jones R N; Lewis M T; Croco M A; Barrett M S
Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Diagnostic microbiology and infectious disease 1999;33(4):275-82.
1999: Jones R N; Kugler K C; Erwin M E; Biedenbach D J; Beach M L; Pfaller M A
Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;33(4):247-53.
1999: Pfaller M A; Messer S A; Hollis R J; Jones R N; Doern G V; Brandt M E; Hajjeh R A
Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States.
Diagnostic microbiology and infectious disease 1999;33(4):217-22.
1999: Diekema D J; Coffman S L; Marshall S A; Beach M L; Rolston K V; Jones R N
Comparison of activities of broad-spectrum beta-lactam compounds against 1,128 gram-positive cocci recently isolated in cancer treatment centers.
Antimicrobial agents and chemotherapy 1999;43(4):940-3.
1999: Marshall S A; Jones R N
Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health.
Diagnostic microbiology and infectious disease 1999;33(3):181-6.
1999: Jones R N; Low D E; Pfaller M A
Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Diagnostic microbiology and infectious disease 1999;33(2):101-12.
1999: Johnson D M; Jones R N; Erwin M E
Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
Diagnostic microbiology and infectious disease 1999;33(2):87-91.
1999: Doern G V; Jones R N; Pfaller M A; Kugler K
Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997).
Antimicrobial agents and chemotherapy 1999;43(2):385-9.
1999: Marshall S A; Jones R N; Erwin M E
Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 1999;33(1):19-25.
1999: Erwin M E; Jones R N
Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group.
Journal of clinical microbiology 1999;37(1):279-80.
1998: Marco F; Pfaller M A; Messer S A; Jones R N
Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
Medical mycology : official publication of the International Society for Human and Animal Mycology 1998;36(6):433-6.
1998: Doern G V; Pfaller M A; Erwin M E; Brueggemann A B; Jones R N
The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program.
Diagnostic microbiology and infectious disease 1998;32(4):313-6.
1998: Biedenbach D J; Beach M L; Jones R N
Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains.
Diagnostic microbiology and infectious disease 1998;32(4):307-11.
1998: Sader H S; Jones R N; Gales A C; Winokur P; Kugler K C; Pfaller M A; Doern G V
Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group.
Diagnostic microbiology and infectious disease 1998;32(4):289-301.
1998: Pfaller M A; Messer S A; Hollis R J; Jones R N; Doern G V; Brandt M E; Hajjeh R A
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Antimicrobial agents and chemotherapy 1998;42(12):3242-4.
1998: Jones R N; Beach M L; Pfaller M A; Doern G V
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Diagnostic microbiology and infectious disease 1998;32(3):247-52.
1998: Croco M A; Biedenbach D J; Pfaller M A; Doern G V; Jones R N
In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp.
The Journal of antimicrobial chemotherapy 1998;42(5):672-3.
1998: DiPersio J R; Jones R N; Barrett T; Doern G V; Pfaller M A
Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998).
Diagnostic microbiology and infectious disease 1998;32(2):131-5.
1998: Jones R N; Pfaller M A; Doern G V
Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
Diagnostic microbiology and infectious disease 1998;32(2):119-26.
1998: Jones R N; Biedenbach D J; Marshall S A; Pfaller M A; Doern G V
Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.
Diagnostic microbiology and infectious disease 1998;32(2):107-10.
1998: Jones R N; Marshall S A; Varnam D J
Activity of a broad-spectrum cephalosporin (Ro 48-8391) alone and in combination with two novel beta-lactamase inhibitors (Ro 48-5545 and Ro 48-8724).
Diagnostic microbiology and infectious disease 1998;32(2):85-94.
1998: Johnson D M; Jones R N; Pfaller M A
Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
The Journal of antimicrobial chemotherapy 1998;42(4):557-9.
1998: Johnson D M; Jones R N
In-vitro activity of a combination of two oral beta-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin.
The Journal of antimicrobial chemotherapy 1998;42(4):555-7.
1998: Doern G V; Pfaller M A; Kugler K; Freeman J; Jones R N
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(4):764-70.
1998: Chen Y S; Marshall S A; Winokur P L; Coffman S L; Wilke W W; Murray P R; Spiegel C A; Pfaller M A; Doern G V; Jones R N
Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistances in enterococci.
Journal of clinical microbiology 1998;36(10):2996-3001.
1998: Jones R N; Erwin M E
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1998;32(1):55-64.
1998: Biedenbach D J; Barrett M S; Croco M A; Jones R N
BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Diagnostic microbiology and infectious disease 1998;32(1):45-50.
1998: Marco F; Pfaller M A; Messer S A; Jones R N
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Diagnostic microbiology and infectious disease 1998;32(1):33-7.
1998: Jones R N; Biedenbach D J; Croco M A; Barrett M S
In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 1998;31(4):573-8.
1998: Cormican M; Corbett-Feeney G; Kelly S; Hughes D; Flynn J; Jones R N
In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates.
Irish journal of medical science 1998;167(3):155-9.
1998: Jones M E; Jones R N; Sader H; Verhoef J; Acar J
Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. Sentry Antimicrobial Surveillance Program.
The Journal of antimicrobial chemotherapy 1998;42(1):119-21.
1998: Pfaller M A; Jones R N; Doern G V; Kugler K
Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997).
Antimicrobial agents and chemotherapy 1998;42(7):1762-70.
1998: Pfaller M A; Jones R N; Doern G V; Sader H S; Hollis R J; Messer S A
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.
Journal of clinical microbiology 1998;36(7):1886-9.
1998: Jones R N
Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes.
Diagnostic microbiology and infectious disease 1998;31(3):461-6.
1998: Jones R N; Wilson W R
Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections.
Diagnostic microbiology and infectious disease 1998;31(3):453-9.
1998: Jones R N; Ballow C H; Biedenbach D J; Deinhart J A; Schentag J J
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Diagnostic microbiology and infectious disease 1998;31(3):437-51.
1998: Jones R N; Pfaller M A
Bacterial resistance: a worldwide problem.
Diagnostic microbiology and infectious disease 1998;31(2):379-88.
1998: Jones R N; Johnson D M
Combinations of orally administered beta-lactams to maximize spectrum and activity against drug-resistant respiratory tract pathogens: I. Synergy studies of amoxicillin and cefixime with Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 1998;31(2):373-6.
1998: Biedenbach D J; Barrett M S; Jones R N
Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.
Diagnostic microbiology and infectious disease 1998;31(2):349-53.
1998: Pfaller M A; Lockhart S R; Pujol C; Swails-Wenger J A; Messer S A; Edmond M B; Jones R N; Wenzel R P; Soll D R
Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates.
Journal of clinical microbiology 1998;36(6):1518-29.
1998: Pfaller M A; Jones R N; Messer S A; Edmond M B; Wenzel R P
National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program.
Diagnostic microbiology and infectious disease 1998;31(1):327-32.
1998: Jones R N; Ballow C H; Schentag J J; Johnson D M; Deinhart J A
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Diagnostic microbiology and infectious disease 1998;31(1):313-25.
1998: Pfaller M A; Marco F; Messer S A; Jones R N
In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.
Diagnostic microbiology and infectious disease 1998;30(4):251-5.
1998: Jones R N; Pfaller M A; Doern G V; Erwin M E; Hollis R J
Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Diagnostic microbiology and infectious disease 1998;30(3):215-28.
1998: Marshall S A; Wilke W W; Pfaller M A; Jones R N
Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program.
Diagnostic microbiology and infectious disease 1998;30(3):205-14.
1998: Barrett M S; Jones R N
Timed kill kinetic studies of levofloxacin, ofloxacin, and ciprofloxacin against Moraxella catarrhalis.
Diagnostic microbiology and infectious disease 1998;30(2):135-7.
1998: Pfaller M A; Jones R N; Messer S A; Edmond M B; Wenzel R P
National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic.
Diagnostic microbiology and infectious disease 1998;30(2):121-9.
1998: Doern G V; Jones R N; Pfaller M A; Erwin M; Ramirez-Rhonda C
Multicenter evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1998;30(2):113-9.
1998: Jensen L B; Ahrens P; Dons L; Jones R N; Hammerum A M; Aarestrup F M
Molecular analysis of Tn1546 in Enterococcus faecium isolated from animals and humans.
Journal of clinical microbiology 1998;36(2):437-42.
1998: Marshall S A; Wilke W W; Chen Y S; Pfaller M A; Jones R N
In vitro activity of cefepime and other broad-spectrum beta-lactams tested against 129 mec A-negative Staphylococcus spp. isolates: a multicenter sample.
Diagnostic microbiology and infectious disease 1998;30(1):65-9.
1998: Pfaller M A; Jones R N; Doern G V
Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1998;30(1):45-52.
1998: Marco F; Pfaller M A; Messer S; Jones R N
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Antimicrobial agents and chemotherapy 1998;42(1):161-3.
1998: Marco F; Pfaller M A; Messer S A; Jones R N
In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi.
Mycopathologia 1998;141(2):73-7.
1997: Pfaller M A; Marshall S A; Jones R N
In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: a multicenter sample.
Diagnostic microbiology and infectious disease 1997;29(4):273-6.
1997: Jones R N; Salazar J C; Pfaller M A; Doern G V
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Diagnostic microbiology and infectious disease 1997;29(4):265-72.
1997: Pfaller M A; Jones R N; Marshall S A; Edmond M B; Wenzel R P
Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group.
Diagnostic microbiology and infectious disease 1997;29(4):259-63.
1997: Cormican M G; Erwin M E; Jones R N
Avoparcin, a glycopeptide used in animal foods: antimicrobial spectrum and potency tested against human isolates from the United States.
Diagnostic microbiology and infectious disease 1997;29(4):241-8.
1997: Biedenbach D J; Jones R N
Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.
Journal of clinical microbiology 1997;35(12):3198-202.
1997: Pfaller M A; Jones R N
Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.
Diagnostic microbiology and infectious disease 1997;29(3):199-201.
1997: Jones R N; Pfaller M A; Marshall S A; Hollis R J; Wilke W W
Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.
Diagnostic microbiology and infectious disease 1997;29(3):187-92.
1997: Ballow C H; Jones R N; Johnson D M; Deinhart J A; Schentag J J
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Diagnostic microbiology and infectious disease 1997;29(3):173-86.
1997: Diekema D J; Barr J; Boyken L D; Buschelman B J; Jones R N; Pfaller M A; Herwaldt L A
A cluster of serious Escherichia coli infections in a neonatal intensive-care unit.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1997;18(11):774-6.
1997: Jones R N; Milazzo J; Seidlin M
Ofloxacin otic solution for treatment of otitis externa in children and adults.
Archives of otolaryngology--head & neck surgery 1997;123(11):1193-200.
1997: Marco F; Barrett M S; Jones R N
Antimicrobial activity of LB20304, a fluoronaphthyridone, tested against anaerobic bacteria.
The Journal of antimicrobial chemotherapy 1997;40(4):605-7.
1997: Jones R N; Marshall S A; Pfaller M A; Wilke W W; Hollis R J; Erwin M E; Edmond M B; Wenzel R P
Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group.
Diagnostic microbiology and infectious disease 1997;29(2):95-102.
1997: Jones R N; Marshall S A; Grimm H
Antimicrobial interactions (synergy) of teicoplanin with two broad-spectrum drugs (cefotaxime, ofloxacin) tested against gram-positive isolates from Germany and the United States.
Diagnostic microbiology and infectious disease 1997;29(2):87-94.
1997: Marco F; Biedenbach D J; Jones R N
Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation.
Diagnostic microbiology and infectious disease 1997;29(1):55-7.
1997: Wilke W W; Marshall S A; Coffman S L; Pfaller M A; Edmund M B; Wenzel R P; Jones R N
Vancomycin-resistant Enterococcus raffinosus: molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program.
Diagnostic microbiology and infectious disease 1997;29(1):43-9.
1997: Pfaller M A; Jones R N; Marshall S A; Coffman S L; Hollis R J; Edmond M B; Wenzel R P
Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).
Diagnostic microbiology and infectious disease 1997;28(4):211-9.
1997: Jones R N; Barrett M S; Deguchi T
Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results.
Diagnostic microbiology and infectious disease 1997;28(4):193-200.
1997: Pfaller M A; Jones R N
A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide.
Diagnostic microbiology and infectious disease 1997;28(4):157-63.
1997: Doern G V; Brueggemann A B; Perla R; Daly J; Halkias D; Jones R N; Saubolle M A
Multicenter laboratory evaluation of the bioMérieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa.
Journal of clinical microbiology 1997;35(8):2115-9.
1997: Flynn C M; Kelley C M; Barrett M S; Jones R N
Application of the Etest to the antimicrobial susceptibility testing of Mycobacterium marinum clinical isolates.
Journal of clinical microbiology 1997;35(8):2083-6.
1997: Saraiva I H; Jones R N; Erwin M; Sader H S
[Evaluation of antimicrobial sensitivity of 87 clinical isolates of vancomycin-resistant enterococci]
Revista da Associação Médica Brasileira (1992) 1997;43(3):217-22.
1997: Putnam S D; Jones R N; Johnson D M
In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Diagnostic microbiology and infectious disease 1997;28(3):139-47.
1997: Putnam L R; Howard W J; Pfaller M A; Koontz F P; Jones R N
Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: use of "direct" inoculation from Bactec 9240 blood culture bottles.
Diagnostic microbiology and infectious disease 1997;28(2):101-4.
1997: Erwin M E; Varnam D; Jones R N
In vitro antimicrobial activity of RU-59863, a C-7 catechol substituted cephalosporin.
Diagnostic microbiology and infectious disease 1997;28(2):93-100.
1997: Klepser M E; Wolfe E J; Jones R N; Nightingale C H; Pfaller M A
Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.
Antimicrobial agents and chemotherapy 1997;41(6):1392-5.
1997: Wittmann D H; Jones R N; Malledant J; Privitera G
Cefotaxime in the treatment of prophylaxis of surgical infections.
Journal of chemotherapy (Florence, Italy) 1997;9 Suppl 2():19-33.
1997: Jones R N; Marshall S A; Zerva L
Critical evaluation of the Vitek GNS F6 card results compared to standardized, reference susceptibility test methods.
Diagnostic microbiology and infectious disease 1997;28(1):35-40.
1997: Jones R N; Dudley M N
Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response.
Diagnostic microbiology and infectious disease 1997;28(1):5-18.
1997: Gales A C; Pignatari A C; Jones R N; Baretta M; Sader H S
[Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteria]
Revista da Associação Médica Brasileira (1992) 1997;43(2):137-44.
1997: Pfaller M A; Jones R N
In vitro evaluation of contemporary beta-lactam drugs tested against viridans group and beta-haemolytic streptococci.
Diagnostic microbiology and infectious disease 1997;27(4):151-4.
1997: Jamjian C; Barrett M S; Jones R N
Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.
Diagnostic microbiology and infectious disease 1997;27(4):129-38.
1997: Marshall S A; Rhomberg P R; Jones R N
Comparative evaluation of etest for susceptibility testing Neisseria meningitidis with eight antimicrobial agents. An investigation using U.S. Food and Drug Administration regulatory criteria.
Diagnostic microbiology and infectious disease 1997;27(3):93-7.
1997: Jones R N; Jacobs M R; Washington J A; Pfaller M A
A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. A 187 clinical laboratory center sample in the United States.
Diagnostic microbiology and infectious disease 1997;27(3):75-83.
1997: Jones R N; Barrett M S; Erwin M E
In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
Antimicrobial agents and chemotherapy 1997;41(2):488-93.
1997: Jamjian C; Biedenbach D J; Jones R N
In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.
Antimicrobial agents and chemotherapy 1997;41(2):454-9.
1997: Pfaller M A; Messer S; Jones R N
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
Antimicrobial agents and chemotherapy 1997;41(2):233-5.
1997: Jones R N
Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections.
Diagnostic microbiology and infectious disease 1997;27(1-2):21-8.
1997: Jones R N; Biedenbach D J
Antimicrobial activity of RU-66647, a new ketolide.
Diagnostic microbiology and infectious disease 1997;27(1-2):7-12.
1997: Biedenbach D J; Schermer I H; Jones R N
Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices.
Diagnostic microbiology and infectious disease 1997;27(1-2):1-5.
1997: Cormican M G; Jones R N
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
Antimicrobial agents and chemotherapy 1997;41(1):204-11.
1996: Flynn C M; Johnson D M; Jones R N
In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
Journal of chemotherapy (Florence, Italy) 1996;8(6):411-5.
1996: Biedenbach D J; Jones R N
Comparative assessment of Etest for testing susceptibilities of Neisseria gonorrhoeae to penicillin, tetracycline, ceftriaxone, cefotaxime, and ciprofloxacin: investigation using 510(k) review criteria, recommended by the Food and Drug Administration.
Journal of clinical microbiology 1996;34(12):3214-7.
1996: Jones R N
Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods.
Diagnostic microbiology and infectious disease 1996;26(2):99-102.
1996: Zerva L; Marshall S A; Jones R N
Premafloxacin: a projected veterinary use fluoro-quinolone with significant activity against multi-resistant gram-positive human pathogens.
The Journal of antimicrobial chemotherapy 1996;38(4):742-4.
1996: Biedenbach D; Wanger A; Jones R N
Comparative in-vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin-and macrolide-resistant pneumococci by the Etest.
The Journal of antimicrobial chemotherapy 1996;38(3):553-5.
1996: Yeo S F; Akalin E; Arikan S; Auckenthaler R; Bergan T; Dornbusch K; Howard A J; Hryniewicz W; Jones R N; Koupari G; Legakis N J; McLaughlin J; Ozkuyumcu C; Percival A; Phillips I; Reeves D; Spencer R; Warren R E; Williams J D
Susceptibility testing of Haemophilus influenzae--an international collaborative study in quality assessment.
The Journal of antimicrobial chemotherapy 1996;38(3):363-86.
1996: Jones R N; Cormican M G; Wanger A
Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 1996;25(4):201-4.
1996: Jones R N
The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance.
Diagnostic microbiology and infectious disease 1996;25(4):153-61.
1996: Marshall S A; Jones R N; Wanger A; Washington J A; Doern G V; Leber A L; Haugen T H
Proposed MIC quality control guidelines for National Committee for Clinical Laboratory Standards susceptibility tests using seven veterinary antimicrobial agents: ceftiofur, enrofloxacin, florfenicol, penicillin G-novobiocin, pirlimycin, premafloxacin, and spectinomycin.
Journal of clinical microbiology 1996;34(8):2027-9.
1996: Zerva L; Biedenbach D J; Jones R N
Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
Journal of clinical microbiology 1996;34(8):1970-4.
1996: Cormican M G; Marshall S A; Jones R N
Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen.
Journal of clinical microbiology 1996;34(8):1880-4.
1996: Cereda R F; Pignatari A C; Leme I L; Jones R N; Sader H S
[In vitro susceptibility testing of 446 clinical isolates of gram-positive bacteria to new quinolones, carbapenems and cephalosporins]
Revista da Associação Médica Brasileira (1992) 1996;42(3):130-4.
1996: Barrett M S; Jones R N
In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species.
Diagnostic microbiology and infectious disease 1996;25(3):147-9.
1996: Johnson D M; Doern G V; Haugen T A; Hindler J; Washington J A; Jones R N
Comparative activity of twelve beta-lactam drugs tested against penicillin-resistant Streptococcus pneumoniae from five medical centers: effects of serum protein and capsular material on potency and spectrum as measured by reference tests.
Diagnostic microbiology and infectious disease 1996;25(3):137-41.
1996: Doern G V; Torres B B; Jankins M; Jones R N
Accurate characterization of ofloxacin susceptibility with Enterobacteriaceae using a modified GNS F6 card and the bioMerieux Vitek System.
Diagnostic microbiology and infectious disease 1996;25(3):133-5.
1996: Cormican M G; Wilke W W; Barrett M S; Pfaller M A; Jones R N
Phenotypic detection of mec A-positive staphylococcal blood stream isolates: high accuracy of simple disk diffusion tests.
Diagnostic microbiology and infectious disease 1996;25(3):107-12.
1996: Jones R N; Erwin M E; Croco J L
Critical appraisal of E test for the detection of fluoroquinolone resistance.
The Journal of antimicrobial chemotherapy 1996;38(1):21-5.
1996: Jones R N
Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.
The American journal of medicine 1996;100(6A):3S-12S.
1996: Biedenbach D J; Jones R N
The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci.
Diagnostic microbiology and infectious disease 1996;25(1):47-51.
1996: Espinel-Ingroff A; Pfaller M; Erwin M E; Jones R N
Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.
Journal of clinical microbiology 1996;34(4):848-52.
1996: Cormican M G; Jones R N
In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates.
The Journal of antimicrobial chemotherapy 1996;37(4):847-9.
1996: Jones R N; Johnson D M; Erwin M E
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.
Antimicrobial agents and chemotherapy 1996;40(3):720-6.
1996: Cormican M G; Erwin M S; Jones R N
Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates.
Diagnostic microbiology and infectious disease 1996;24(3):169-72.
1996: Cormican M G; Erwin M E; Marshall S A; Jones R N
Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis.
Diagnostic microbiology and infectious disease 1996;24(3):155-60.
1996: Worth S; Erwin M E; Jones R N
Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials.
Diagnostic microbiology and infectious disease 1996;24(2):87-91.
1996: Cormican M G; Erwin M E; Jones R N
False resistance to metronidazole by E-test among anaerobic bacteria investigations of contributing test conditions and medium quality.
Diagnostic microbiology and infectious disease 1996;24(2):117-9.
1996: Barrett M S; Jones R N
Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
Diagnostic microbiology and infectious disease 1996;24(2):113-6.
1996: Howard W J; Buschelman B J; Bale M J; Pfaller M A; Koontz F P; Jones R N
Vitek GPS card susceptibility testing accuracy using direct inoculation from BACTEC 9240 blood culture bottles.
Diagnostic microbiology and infectious disease 1996;24(2):109-12.
1996: Mehaffey P C; Putnam S D; Barrett M S; Jones R N
Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods.
Journal of clinical microbiology 1996;34(2):479-81.
1996: Cormican M G; Johnson D M; Jones R N
Activity of the quinupristin-dalfopristin combination (RP-59500; Synercid) tested against vancomycin-resistant Enterococcus species.
Diagnostic microbiology and infectious disease 1996;24(1):59-60.
1996: Johnson D M; Jones R N
Two investigational glycylcyclines, DMG-DMDOT and DMG-MINO. Antimicrobial activity studies against gram-positive species.
Diagnostic microbiology and infectious disease 1996;24(1):53-7.
1996: Cormican M G; Jones R N
Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.
Drugs 1996;51 Suppl 1():6-12.
1995: Cormican M G; Marshall S A; Jones R N
Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agents.
Diagnostic microbiology and infectious disease 1995;23(4):157-60.
1995: Jones R N; Johnson D M; Biedenbach D J; Marshall S A
Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
Diagnostic microbiology and infectious disease 1995;23(3):123-7.
1995: Sader H S; Jones R N; Pfaller M A
Relapse of catheter-related Flavobacterium meningosepticum bacteremia demonstrated by DNA macrorestriction analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;21(4):997-1000.
1995: Biedenbach D J; Sutton L D; Jones R N
Antimicrobial activity of CS-940, a new trifluorinated quinolone.
Antimicrobial agents and chemotherapy 1995;39(10):2325-30.
1995: Murphy S P; Cormican M G; Jones R N
Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
Irish journal of medical science 1995;164(4):271-3.
1995: Mehaffey P C; Barrett M S; Putnam S D; Jones R N
Antigonococcal activity of 11 drugs used for therapy or prophylaxis of malaria.
Diagnostic microbiology and infectious disease 1995;23(1-2):11-13.
1995: Marshall S A; Sutton L D; Jones R N
Evaluation of S1 chromogenic cephalosporin beta-lactamase disk assay tested against gram-positive anaerobes, coagulase-negative staphylococci, Prevotella spp. and Enterococcus spp.
Diagnostic microbiology and infectious disease 1995;22(4):353-5.
1995: Sader H S; Biedenbach D; Jones R N
Evaluation of Vitek and API 20S for species identification of enterococci.
Diagnostic microbiology and infectious disease 1995;22(4):315-9.
1995: Cormican M G; Jones R N
Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
The Journal of antimicrobial chemotherapy 1995;36(2):431-4.
1995: Cormican M G; Jones R N
Use of a multiplex PCR to detect and identify Mycobacterium avium and M. intracellulare in blood culture fluids of AIDS patients.
Journal of clinical microbiology 1995;33(8):2230.
1995: Jones R N
Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.
The Pediatric infectious disease journal 1995;14(7 Suppl):S77-83.
1995: Biedenbach D J; Jones R N
In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.
Antimicrobial agents and chemotherapy 1995;39(7):1636-42.
1995: Jones R N
Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity.
Journal of chemotherapy (Florence, Italy) 1995;7 Suppl 2():7-16.
1995: Doern G V; Jones R N; Gerlach E H; Washington J A; Biedenbach D J; Brueggemann A; Erwin M E; Knapp C; Raymond J
Multicenter clinical laboratory evaluation of a beta-lactamase disk assay employing a novel chromogenic cephalosporin, S1.
Journal of clinical microbiology 1995;33(6):1665-7.
1995: Cormican M G; Runyon B A; Jones R N
In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis.
Journal of chemotherapy (Florence, Italy) 1995;7(3):197-200.
1995: Croco J L; Erwin M E; Jennings J M; Putnam L R; Jones R N
Evaluation of the Etest for determinations of antimicrobial spectrum and potency against anaerobes associated with bacterial vaginosis and peritonitis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;20 Suppl 2():S339-41.
1995: Cormican M G; Jones R N
Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens).
Diagnostic microbiology and infectious disease 1995;22(1-2):43-8.
1995: Jones R N
Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
Diagnostic microbiology and infectious disease 1995;22(1-2):19-33.
1995: Cormican M G; Erwin M E; Jones R N
Bactericidal activity of cefotaxime, desacetylcefotaxime, rifampin, and various combinations tested at cerebrospinal fluid levels against penicillin-resistant Streptococcus pneumoniae.
Diagnostic microbiology and infectious disease 1995;22(1-2):119-23.
1995: Wilke W W; Sutton L D; Jones R N
Automation of polymerase chain reaction tests to achieve acceptable contamination rates.
Clinical chemistry 1995;41(4):622-3.
1995: Cormican M G; Jones R N
Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and beta-lactamase producing bacteria.
The Journal of antimicrobial chemotherapy 1995;35(4):535-9.
1995: Cormican M G; Jones R N
Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
Diagnostic microbiology and infectious disease 1995;21(4):227-30.
1995: Jones R N; Johnson D M
Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
Diagnostic microbiology and infectious disease 1995;21(4):209-13.
1995: Wilke W W; Jones R N; Sutton L D
Automation of polymerase chain reaction tests. Reduction of human errors leading to contamination.
Diagnostic microbiology and infectious disease 1995;21(4):181-5.
1995: Sader H S; Jones R N
[Cephalosporins: 4 generations of structural evolution]
Revista da Associação Médica Brasileira (1992) 1995;41(2):144-50.
1995: Marshall S A; Aldridge K E; Allen S D; Fuchs P C; Gerlach E H; Jones R N
Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.
Diagnostic microbiology and infectious disease 1995;21(3):153-68.
1995: Baron E J; Jones R N
National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.
Diagnostic microbiology and infectious disease 1995;21(3):141-51.
1995: Jones R N
Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1995;52(6 Suppl 2):S29-33.
1995: Jones R N; Erwin M E; Anderson S C
Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strains.
Diagnostic microbiology and infectious disease 1995;21(2):95-100.
1995: Jones R N; Sader H S; Erwin M E; Anderson S C
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.
Diagnostic microbiology and infectious disease 1995;21(2):85-93.
1995: Sader H S; Runyon B A; Erwin M E; Jones R N
Antimicrobial activity of 11 newer and investigational drugs tested against aerobic isolates from spontaneous bacterial peritonitis.
Diagnostic microbiology and infectious disease 1995;21(2):105-10.
1995: Hoban D J; Jones R N
Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group.
Chemotherapy 1995;41(1):34-8.
1995: Biedenbach D J; Jones R N
Interpretive errors using an automated system for the susceptibility testing of imipenem and aztreonam.
Diagnostic microbiology and infectious disease 1995;21(1):57-60.
1995: Cormican M G; Marshall S A; Jones R N
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Diagnostic microbiology and infectious disease 1995;21(1):51-4.
1995: Sutton L D; Biedenbach D J; Yen A; Jones R N
Development, characterization, and initial evaluations of S1. A new chromogenic cephalosporin for beta-lactamase detection.
Diagnostic microbiology and infectious disease 1995;21(1):1-8.
1995: Cormican M G; Jones R N
Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.
Journal of clinical microbiology 1995;33(1):215-6.
1995: Sutton L D; Jones R N
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
Journal of clinical microbiology 1995;33(1):146-8.
1995: Jones R N
In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone.
Drugs 1995;49 Suppl 2():205-7.
1995: Jones R N; Kehrberg E N; Erwin M E
Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres.
Drugs 1995;49 Suppl 2():179-81.
1994: Sanford M D; Widmer A F; Bale M J; Jones R N; Wenzel R P
Efficient detection and long-term persistence of the carriage of methicillin-resistant Staphylococcus aureus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1994;19(6):1123-8.
1994: Croco J L; Erwin M E; Jennings J M; Putnam L R; Jones R N
Evaluation of the Etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis.
Diagnostic microbiology and infectious disease 1994;20(4):213-9.
1994: Sader H S; Pfaller M A; Jones R N
Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Diagnostic microbiology and infectious disease 1994;20(4):203-8.
1994: Jones R N
Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.
Diagnostic microbiology and infectious disease 1994;20(3):167-70.
1994: Rhomberg P R; Jones R N
Evaluations of the Etest for antimicrobial susceptibility testing of Legionella pneumophila, including validation of the imipenem and sparfloxacin strips.
Diagnostic microbiology and infectious disease 1994;20(3):159-62.
1994: Jones R N; Sutton L D; Cantrell H F; Lankford R B
Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
Diagnostic microbiology and infectious disease 1994;20(3):143-9.
1994: Sader H S; Pfaller M A; Tenover F C; Hollis R J; Jones R N
Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers.
Journal of clinical microbiology 1994;32(11):2840-2.
1994: Jones R N; Sader H S; Erwin M E
Update of lomefloxacin in vitro activity and spectrum. A multicenter trial testing contemporary pathogens following Food and Drug Administration validation guidelines. Lomefloxacin Activity Study Group.
Diagnostic microbiology and infectious disease 1994;20(2):93-8.
1994: Murphy S P; Erwin M E; Jones R N
Cefquinome (HR 111V). In vitro evaluation of a broad-spectrum cephalosporin indicated for infections in animals.
Diagnostic microbiology and infectious disease 1994;20(1):49-55.
1994: Jones R N; Kehrberg E N; Erwin M E; Anderson S C
Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.
Diagnostic microbiology and infectious disease 1994;19(4):203-15.
1994: Sader H S; Jones R N
In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1994;13(8):675-9.
1994: Koontz F P; Erwin M E; Barrett M S; Jones R N
Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.
Diagnostic microbiology and infectious disease 1994;19(3):183-6.
1994: Rhomberg P R; Bale M J; Jones R N
Application of the Etest to antimicrobial susceptibility testing of Legionella spp.
Diagnostic microbiology and infectious disease 1994;19(3):175-8.
1994: Sader H S; Perl T M; Hollis R J; Divishek D; Herwaldt L A; Jones R N
Nosocomial transmission of Serratia odorifera biogroup. 2: Case report demonstration by macrorestriction analysis of chromosomal DNA using pulsed-field gel electrophoresis.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1994;15(6):390-3.
1994: Doern G V; Jones R N; Gerlach E H; Hindler J; St Amand R
Revised disk diffusion interpretive criteria for cefaclor, loracarbef, cefprozil and cefixime when testing Haemophilus influenzae on haemophilus test medium.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1994;13(6):481-9.
1994: Jones R N; Barrett M S; Biedenbach D J
Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
Diagnostic microbiology and infectious disease 1994;19(2):93-9.
1994: Bale M J; Jones R N; Erwin M E
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.
Diagnostic microbiology and infectious disease 1994;19(1):65-8.
1994: Jones R N; Marshall S A
Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.
Diagnostic microbiology and infectious disease 1994;19(1):33-8.
1994: Sader H S; Pignatari A C; Hollis R J; Jones R N
Evaluation of interhospital spread of methicillin-resistant Staphylococcus aureus in Sao Paulo, Brazil, using pulsed-field gel electrophoresis of chromosomal DNA.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1994;15(5):320-3.
1994: Bale M; Jones R N
Antibacterial features of lubraseptic jelly.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1994;15(4 Pt 1):225.
1994: Yamane N; Jones R N; Frei R; Hoban D J; Pignatari A C; Marco F
Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.
Journal of chemotherapy (Florence, Italy) 1994;6(2):83-91.
1994: Jones R N
Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks.
Journal of clinical microbiology 1994;32(4):1104-6.
1994: Jones R N; Doern G V; Gerlach E H; Hindler J; Erwin M E
Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.
Diagnostic microbiology and infectious disease 1994;18(4):243-9.
1994: Marco F; Jones R N; Hoban D J; Pignatari A C; Yamane N; Frei R
In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.
The Journal of antimicrobial chemotherapy 1994;33(3):647-54.
1994: Frei R; Jones R N; Pignatari A C; Yamane N; Marco F; Hoban D J
Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
Diagnostic microbiology and infectious disease 1994;18(3):167-73.
1994: Perl T M; Rhomberg P R; Bale M J; Fuchs P C; Jones R N; Koontz F P; Pfaller M A
Comparison of identification systems for Staphylococcus epidermidis and other coagulase-negative Staphylococcus species.
Diagnostic microbiology and infectious disease 1994;18(3):151-5.
1994: Sader H S; Pignatari A C; Frei R; Hollis R J; Jones R N
Pulsed-field gel electrophoresis of restriction-digested genomic DNA and antimicrobial susceptibility of Xanthomonas maltophilia strains from Brazil, Switzerland and the USA.
The Journal of antimicrobial chemotherapy 1994;33(3):615-8.
1994: Buschelman B J; Jones R N; Bale M J
Effects of blood medium supplements on activities of newer cephalosporins tested against enterococci.
Journal of clinical microbiology 1994;32(2):565-7.
1994: Biedenbach D J; Jones R N
Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef.
Journal of clinical microbiology 1994;32(2):559-62.
1994: Houston A K; Jones R N
Post-antibiotic effect of FK-037 and biapenem tested against five bacterial species.
Journal of chemotherapy (Florence, Italy) 1994;6(1):12-4.
1994: Jones R N
False resistance to aminoglycosides, a national susceptibility testing problem?
Diagnostic microbiology and infectious disease 1994;18(2):133-5.
1994: Jones R N; Johnson D M; Erwin M E
Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
Diagnostic microbiology and infectious disease 1994;18(2):125-7.
1994: Jones R N; Barrett M S; Erwin M E
In-vitro activity of FK-037, a new parenteral cephalosporin.
The Journal of antimicrobial chemotherapy 1994;33(1):137-44.
1994: Jones R N; Sanchez M L
Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
Diagnostic microbiology and infectious disease 1994;18(1):61-8.
1994: Houston A K; Jones R N
Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
Diagnostic microbiology and infectious disease 1994;18(1):57-9.
1994: Jones R N; Hoban D J
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
Diagnostic microbiology and infectious disease 1994;18(1):49-56.
1994: Jones R N
The injectable cephalosporins in the treatment of serious infections.
Infection 1994;22 Suppl 3():S182-3.
1994: Jones R N
The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.
Infection 1994;22 Suppl 3():S152-60.
1993: Hughes J H; Biedenbach D J; Erwin M E; Jones R N
E test as susceptibility test and epidemiologic tool for evaluation of Neisseria meningitidis isolates.
Journal of clinical microbiology 1993;31(12):3255-9.
1993: Sanford M D; Jones R N
Postantibiotic effects of E-4868 and OPC-17116.
The Journal of antimicrobial chemotherapy 1993;32(6):916-7.
1993: Marshall S A; Jones R N; Murray P R; Washington J A; Allen S D; Gerlach E H; Erwin M E
In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
The Journal of antimicrobial chemotherapy 1993;32(6):877-84.
1993: Marshall S A; Jones R N
In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.
Antimicrobial agents and chemotherapy 1993;37(12):2747-53.
1993: Jones R N; Zurenko G E
Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.
Diagnostic microbiology and infectious disease 1993;17(4):313-6.
1993: Murray P R; Jones R N; Washington J A; Gerlach E H; Allen S D
In vitro comparison of E4868, a new trifluoroquinolone, with ciprofloxacin and temafloxacin tested against 5192 recent clinical isolates from five medical centers.
Diagnostic microbiology and infectious disease 1993;17(4):307-11.
1993: Hoban D J; Jones R N; Yamane N; Frei R; Trilla A; Pignatari A C
In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.
Diagnostic microbiology and infectious disease 1993;17(4):299-305.
1993: Sanchez M L; Jones R N
Antimicrobial activity of FK-037 against class I beta-lactamase producing species resistant to ceftazidime: a multi-laboratory clinical isolate sample.
The Journal of antimicrobial chemotherapy 1993;32(4):654-6.
1993: Erwin M E; Jones R N
Roxithromycin in-vitro susceptibility testing of Haemophilus influenzae by NCCLS methods. National Committee for Clinical Laboratory Standards.
The Journal of antimicrobial chemotherapy 1993;32(4):652-4.
1993: Biedenbach D J; Jones R N; Erwin M E
Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.
Journal of clinical microbiology 1993;31(10):2828-30.
1993: Barrett M S; Jones R N; Erwin M E
Interpretive criteria for cefodizime in vitro susceptibility tests with Neisseria gonorrhoeae.
Diagnostic microbiology and infectious disease 1993;17(3):243-5.
1993: Jones R N; Erwin M E; Hager H L; Hohl P E
Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials.
Diagnostic microbiology and infectious disease 1993;17(3):225-32.
1993: Sader H S; Jones R N; Allen S D; Gerlach E H; Murray P R; Washington J A
In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers.
Journal of chemotherapy (Florence, Italy) 1993;5(5):283-8.
1993: Bale M J; Jones R N
Quality control guidelines for cefdinir, cefepime, cefetamet, cefmetazole, cefpodoxime, cefprozil, and clinafloxacin (CI-960) for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Quality Control Study Group.
Journal of clinical microbiology 1993;31(9):2538-40.
1993: Barrett M S; Jones R N; Erwin M E
Ceftizoxime interpretive criteria for in vitro susceptibility tests with Neisseria gonorrhoeae.
Journal of clinical microbiology 1993;31(9):2531-2.
1993: Hoban D J; Jones R N; Harrell L J; Knudson M; Sewell D
The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.
Diagnostic microbiology and infectious disease 1993;17(2):157-61.
1993: Sader H S; Jones R N; Washington J A; Murray P R; Gerlach E H; Allen S D; Erwin M E
In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
Diagnostic microbiology and infectious disease 1993;17(2):143-50.
1993: Washington J A; Jones R N; Gerlach E H; Murray P R; Allen S D; Knapp C C
Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.
Antimicrobial agents and chemotherapy 1993;37(8):1696-700.
1993: Johnson D M; Jones R N; Erwin M E
In vitro antimicrobial activity of CP-99433 compared with other fluoroquinolones.
Diagnostic microbiology and infectious disease 1993;17(1):79-83.
1993: Doern G V; Jones R N
In vitro susceptibility test practices with Haemophilus influenzae among College of American Pathologists survey participants in the United States.
Diagnostic microbiology and infectious disease 1993;17(1):61-5.
1993: Jones R N; Bale M J; Hoban D; Erwin M E
In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 6.5%) application.
Diagnostic microbiology and infectious disease 1993;17(1):45-51.
1993: Sader H S; Pignatari A C; Leme I L; Burattini M N; Tancresi R; Hollis R J; Jones R N
Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit.
Diagnostic microbiology and infectious disease 1993;17(1):13-8.
1993: Sader H S; Pignatari A C; Hollis R J; Leme I; Jones R N
Oxacillin- and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil: a multicenter molecular epidemiology study.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 1993;14(5):260-4.
1993: Sader H S; Jones R N
Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(5):384-91.
1993: Buschelman B J; Jones R N
Newer glycopeptide antibiotics tested against nosocomial bloodstream isolates.
The Journal of antimicrobial chemotherapy 1993;31(3):445-7.
1993: Sanchez M L; Flint K K; Jones R N
Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem?
Diagnostic microbiology and infectious disease 1993;16(3):205-13.
1993: Murray P R; Jones R N; Allen S D; Erwin M E; Fuchs P C; Gerlach E H
Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria.
Diagnostic microbiology and infectious disease 1993;16(3):191-203.
1993: Widmer A F; Wenzel R P; Trilla A; Bale M J; Jones R N; Doebbeling B N
Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: probable transmission via hands of a health care worker.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;16(3):372-6.
1993: Buschelman B J; Bale M J; Jones R N
Species identification and determination of high-level aminoglycoside resistance among enterococci. Comparison study of sterile body fluid isolates, 1985-1991.
Diagnostic microbiology and infectious disease 1993;16(2):119-22.
1993: Ena J; Houston A; Wenzel R P; Jones R N
Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital.
Journal of chemotherapy (Florence, Italy) 1993;5(1):17-21.
1993: Barrett M S; Jones R N; Erwin M E
In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(2):134-41.
1993: Hoover W W; Gerlach E H; Hoban D J; Eliopoulos G M; Pfaller M A; Jones R N
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.
Diagnostic microbiology and infectious disease 1993;16(2):111-8.
1993: Ena J; Dick R W; Jones R N; Wenzel R P
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study.
JAMA : the journal of the American Medical Association 1993;269(5):598-602.
1993: Gooding B B; Jones R N
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
Antimicrobial agents and chemotherapy 1993;37(2):349-53.
1993: Rodrigues J N; Amaral J L; Leme I L; Pignatari A; Wey S; Hollis R; Pfaller M A; Jones R N
Molecular epidemiology and antimicrobial susceptibility testing. Testing of quinolone-resistant Staphylococcus aureus strains isolated in Brazil.
Diagnostic microbiology and infectious disease 1993;16(1):9-16.
1993: Acar J F; O'Brien T F; Goldstein F W; Jones R N
The epidemiology of bacterial resistance to quinolones.
Drugs 1993;45 Suppl 3():24-8.
1992: Jones R N; Erwin M E
Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin.
Diagnostic microbiology and infectious disease 1992;15(8):693-701.
1992: Barrett M S; Jones R N
Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae.
Diagnostic microbiology and infectious disease 1992;15(8):685-91.
1992: Thrupp L D; Cleeland R; Jones R N; Novick W J; Reller L B; Thornsberry C L; Washington J A
General guidelines for clinical bacteriology. Infectious Diseases Society of America and the Food and Drug Administration.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1992;15 Suppl 1():S339-46.
1992: Sanchez M L; Barrett M S; Jones R N
Use of the E test to predict high-level resistance to aminoglycosides among enterococci.
Journal of clinical microbiology 1992;30(11):3030-2.
1992: Sader H S; Jones R N
Cefotaxime is extensively used for surgical prophylaxis.
American journal of surgery 1992;164(4A Suppl):28S-38S.
1992: Barrett M S; Wenzel R P; Jones R N
In vitro activity of mersacidin (M87-1551), an investigational peptide antibiotic tested against gram-positive bloodstream isolates.
Diagnostic microbiology and infectious disease 1992;15(7):641-4.
1992: Jones R N; Erwin M E; Washington J A; Koontz F P; Murray P R; Gerlach E H
Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae.
Diagnostic microbiology and infectious disease 1992;15(7):627-32.
1992: Gooding B B; Erwin M E; Barrett M S; Johnson D M; Jones R N
Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.
Antimicrobial agents and chemotherapy 1992;36(9):2049-50.
1992: Johnson D M; Erwin M E; Barrett M S; Gooding B B; Jones R N
Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(8):751-5.
1992: Gerlach E H; Jones R N; Allen S D; Koontz F P; Murray P R; Pfaller M A; Washington J A; Erwin M E
Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.
Diagnostic microbiology and infectious disease 1992;15(6):537-43.
1992: Jones R N; Erwin M E
In vitro activity of CP-74667 compared with four other fluoroquinolones.
Diagnostic microbiology and infectious disease 1992;15(6):531-6.
1992: Aldridge K E; Jones R N; Barry A L; Gelfand M S
In vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains.
Diagnostic microbiology and infectious disease 1992;15(6):517-21.
1992: Sanchez M L; Barrett M S; Jones R N
The E-Test applied to susceptibility tests of gonococci, multiply-resistant enterococci, and Enterobacteriaceae producing potent beta-lactamases.
Diagnostic microbiology and infectious disease 1992;15(5):459-63.
1992: Jones R N; Reller L B; Rosati L A; Erwin M E; Sanchez M L
Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
Diagnostic microbiology and infectious disease 1992;15(5):425-34.
1992: Jones R N
Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity.
The Journal of antimicrobial chemotherapy 1992;29(6):725-7.
1992: Ephtimios I E; Barrett M S; Wenzel R P; Jones R N
In-vitro antimicrobial activity of the penem BRL-42715, alone and in combination with ampicillin, against respiratory tract pathogens.
The Journal of antimicrobial chemotherapy 1992;29(5):599-600.
1992: Perl T M; Wenzel R P; Jones R N
In-vitro activity of LY264826, an investigational glycopeptide antibiotic, against gram-positive bloodstream isolates and selected gram-negative bacilli.
The Journal of antimicrobial chemotherapy 1992;29(5):596-8.
1992: Jones R N; Erwin M E
Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin.
Journal of clinical microbiology 1992;30(5):1297-300.
1992: Barrett M S; Jones R N
Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(5):462-5.
1992: Jones R N; Erwin M E; Barrett M S
Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
Diagnostic microbiology and infectious disease 1992;15(4):379-81.
1992: Erwin M E; Jones R N; Koontz F P; Gerlach E H; Murray P R; Washington J A
MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin.
Journal of clinical microbiology 1992;30(5):1317-9.
1992: Erwin M E; Jones R N
Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
Journal of clinical microbiology 1992;30(5):1170-3.
1992: Croco J L; Jones R N
Alternative antimicrobial agents to contemporary treatment of infections caused by Corynebacterium parvum (Propionibacterium acnes)
The Journal of antimicrobial chemotherapy 1992;29(4):471-3.
1992: Jones R N
Proposed cefepime interpretive criteria for in-vitro susceptibility tests with Neisseria gonorrhoeae.
The Journal of antimicrobial chemotherapy 1992;29(4):464-6.
1992: Jones R N; Erwin M E; Gooding B B
Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates.
Journal of clinical microbiology 1992;30(4):1022-3.
1992: Sanchez M L; Wenzel R P; Jones R N
In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.
Antimicrobial agents and chemotherapy 1992;36(4):873-5.
1992: Sader H S; Erwin M E; Jones R N
In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(4):372-81.
1992: Jones R N
Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity.
The American journal of medicine 1992;92(4A):52S-57S.
1992: Hoover W W; Barrett M S; Jones R N
Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin.
Diagnostic microbiology and infectious disease 1992;15(3):259-66.
1992: Bale M J; Jones R N; Erwin M E; Koontz F P; Gerlach E H; Murray P R; Washington J A
Disk diffusion quality control guidelines for Haemophilus susceptibility tests using cefdinir, CI-960, fleroxacin, temafloxacin, and trospectomycin.
Journal of clinical microbiology 1992;30(3):744-5.
1992: Neu H C; Duma R J; Jones R N; McGowan J E; O'Brien T F; Sabath L D; Sanders C C; Schaffner W; Tally F P; Tenover F C
Antibiotic resistance. Epidemiology and therapeutics.
Diagnostic microbiology and infectious disease 1992;15(2 Suppl):53S-60S.
1992: Neu H C; Duma R J; Jones R N; McGowan J E; O'Brien T F; Sabath L D; Sanders C C; Schaffner W; Tenover F C; Young L S
Therapeutic and epidemiologic recommendations to reduce the spread of type-I beta-lactamase resistance.
Diagnostic microbiology and infectious disease 1992;15(2 Suppl):49S-52S.
1992: Jones R N
The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens.
Diagnostic microbiology and infectious disease 1992;15(2 Suppl):3S-10S.
1992: Jones R N
Preliminary interpretive criteria for the Haemophilus Test Medium method using 30 micrograms cefepime disks.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(2):207-8.
1992: Johnson D M; Jones R N
Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(2):181-8.
1992: Jones R N
In vitro evaluation of E-4695, a new fluoro-naphthyridine.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(2):188-94.
1992: Jones R N
Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians?
Diagnostic microbiology and infectious disease 1992;15(2):177-9.
1992: Barrett M S; Jones R N; Erwin M E; Koontz F P
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum.
Diagnostic microbiology and infectious disease 1992;15(2):169-71.
1992: Pfaller M A; Jones R N; Washington J A; Koontz F P; Gerlach E H; Erwin M E
Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.
Diagnostic microbiology and infectious disease 1992;15(2):145-50.
1992: Jones R N; Erwin M E
In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin.
Antimicrobial agents and chemotherapy 1992;36(1):233-8.
1992: Jones R N; Erwin M E; Bale M
New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria.
Diagnostic microbiology and infectious disease 1992;15(1):73-80.
1992: Hardy D J; Guay D R; Jones R N
Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview.
Diagnostic microbiology and infectious disease 1992;15(1):39-53.
1992: Bale M J; Jones R N; Erwin M E; Koontz F P; Gerlach E H; Murray P R; Washington J A
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.
Journal of clinical microbiology 1992;30(1):225-6.
1991: Jones R N
Antimicrobial activity of Ro 41-1879, a new catechol cephalosporin.
Journal of chemotherapy (Florence, Italy) 1991;3(6):339-42.
1991: Jones R N; Erwin M E
Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporin.
Journal of clinical microbiology 1991;29(12):2890-2.
1991: Jones R N; Erwin M E; Barrett M S
Antimicrobial activity of three investigational oral cephalosporins (BK-218, cefdinir, and RU29246) against Legionella.
Diagnostic microbiology and infectious disease 1991;14(6):519-21.
1991: Jones R N; Erwin M E; Barrett M S; Briggs B M; Johnson D M
In vitro activity of RU29246. The metabolite of a new HR916 cephalosporin ester.
Diagnostic microbiology and infectious disease 1991;14(6):473-83.
1991: Jones R N; Johnson D M; Barrett M S; Erwin M E
Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci.
Journal of chemotherapy (Florence, Italy) 1991;3(5):289-94.
1991: Wenzel R P; Nettleman M D; Jones R N; Pfaller M A
Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures.
The American journal of medicine 1991;91(3B):221S-227S.
1991: Murray P R; Allen S D; Erwin M E; Gerlach E H; Jones R N; Koontz F P; Pfaller M A; Washington J A
Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(9):776-81.
1991: Briggs B M; Jones R N; Erwin M E; Barrett M S; Johnson D M
In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
Diagnostic microbiology and infectious disease 1991;14(5):425-34.
1991: Jones R N; Gerlach E H; Koontz F P; Murray P R; Pfaller M A; Washington J A; Erwin M E; Knapp C C
Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines.
Diagnostic microbiology and infectious disease 1991;14(5):383-8.
1991: Barrett M S; Jones R N; Erwin M E; Johnson D M; Briggs B M
Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
Diagnostic microbiology and infectious disease 1991;14(5):389-401.
1991: Washington J A; Jones R N; Allen S D; Gerlach E H; Koontz F P; Murray P R; Pfaller M A; Erwin M E
In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolates.
Antimicrobial agents and chemotherapy 1991;35(7):1508-11.
1991: Jones R N; Erwin M E
False resistance results using 5 micrograms cefixime disks to test Haemophilus influenzae.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1991;10(7):596-7.
1991: Jones R N; Barrett M S; Erwin M E; Briggs B M; Johnson D M
In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Diagnostic microbiology and infectious disease 1991;14(4):319-30.
1991: Jones R N; Pfaller M A; Allen S D; Gerlach E H; Fuchs P C; Aldridge K E
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centers.
Diagnostic microbiology and infectious disease 1991;14(4):361-4.
1991: Yamane N; Jones R N
In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.
Diagnostic microbiology and infectious disease 1991;14(4):337-45.
1991: Jones R N; Erwin M E; Barrett M S; Johnson D M; Briggs B M
Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
Diagnostic microbiology and infectious disease 1991;14(4):301-9.
1991: Jones R N; Edson D C
Antimicrobial susceptibility testing trends and accuracy in the United States. A review of the College of American Pathologists Microbiology Surveys, 1972-1989. Microbiology Resource Committee of the College of American Pathologists.
Archives of pathology & laboratory medicine 1991;115(5):429-36.
1991: Erwin M E; Jones R N; Barrett M S; Briggs B M; Johnson D M
In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin.
Antimicrobial agents and chemotherapy 1991;35(5):929-37.
1991: Pignatari A; Jones R N; Barrett M R; Sesso R; Leme I; Pfaller M A
Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD-associated Staphylococcus aureus infection.
Journal of chemotherapy (Florence, Italy) 1991;3(2):108-16.
1991: Jones R N; Washington J A; Pfaller M A; Koontz F P; Gerlach E H; Erwin M E
Quality control guidelines for Haemophilus test medium MIC susceptibility tests with cefmetazole, cefpodoxime, CI-960 (PD127391, AM-1090), and RU29246.
The Journal of antimicrobial chemotherapy 1991;27(3):390-2.
1991: Jones R N
Activity of sparfloxacin (AT-4140), PD127391 and PD131628 against Legionella spp.
The Journal of antimicrobial chemotherapy 1991;27(3):389-90.
1991: Jones R N; Goldstein F W; Zhou X Y
Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States.
Antimicrobial agents and chemotherapy 1991;35(3):584-6.
1991: Jones R N; Gerlach E H; Koontz F P; Murray P R; Pfaller M A; Washington J A; Erwin M E; Knapp C C
Interpretive criteria and quality control guidelines for Neisseria gonorrhoeae susceptibility test standardization for cefotetan.
Journal of clinical microbiology 1991;29(2):363-6.
1991: Jones R N
Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720)--a review of United States and Canadian results.
Diagnostic microbiology and infectious disease 1991;14(1):37-43.
1991: Jones R N
Microbiological conclusions.
Drugs 1991;42 Suppl 3():22-4.
1990: Mitchell P S; Huston B J; Jones R N; Holcomb L; Koontz F P
Stomatococcus mucilaginosus bacteremias. Typical case presentations, simplified diagnostic criteria, and a literature review.
Diagnostic microbiology and infectious disease 1990;13(6):521-5.
1990: Jones R N
Role of new cephamycins in the management of obstetric and gynecologic infections.
The Journal of reproductive medicine 1990;35(11 Suppl):1070-7.
1990: Jones R N; Erwin M E; Barrett M S
In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1990;9(11):846-8.
1990: Jones R N; Fuchs P C; Washington J A; Gavan T L; Murray P R; Gerlach E H; Thornsberry C
Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae.
Diagnostic microbiology and infectious disease 1990;13(6):499-507.
1990: Barry A L; Jones R N
In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci.
Antimicrobial agents and chemotherapy 1990;34(9):1830-2.
1990: Jones R N; Croco J L; Barrett M S; Novick W J; Erwin M E
Antimicrobial spectrum of cefpirome combined with tazobactam against the Bacteroides fragilis group.
Diagnostic microbiology and infectious disease 1990;13(5):371-3.
1990: Jones R N
Broth-disk elution tests to predict the susceptibility of anaerobic bacteria to the ampicillin-sulbactam combination.
Diagnostic microbiology and infectious disease 1990;13(4):353-5.
1990: Jones R N
Review of cefotaxime sodium for surgical prophylaxis. A model for the evolution toward single-dose or short-course cost-effective regimens.